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Chapter 1  
 
Introduction 
 
1-1 Preface 
 
Substrate is a molecule upon which an enzyme acts. Enzymes catalyze chemical reactions 
involving the substrate(s). In the case of a single substrate, the substrate binds with the 
enzyme active site, and an enzyme-substrate complex is formed. The substrate is 
transformed into one or more products, which are then released from the active site. In 
competitive inhibition, the inhibitor and substrate compete for the enzyme. Often 
competitive inhibitors resemble in their structures with the real substrate of the enzyme. 
 
Fluorescent substrate is a good tool for measuring the protease activity. Briefly, it changes 
the fluorescence property or chromogenic property of the dye label evaluated upon the 
cleavage of amide bond of the substrate by a specific enzyme. Measuring the degree of 
those changes, the activity of target enzyme could be understood. In the paper it just few 
words, but this kind of measurement have a huge background. 
 
1-2 Casein assay 
 
As one classical enzymatic hydrolysis of fluorescent substrate, fluorescein isothiocyanate 
(FITC)-casein is widely used for fluorometric measurement of protease activity.  
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Casein is one of the main protein in the 
milk. In cow's milk, casein makes up 
almost 82% of milk protein and in 
human milk it takes 65% of total protein. 
[1] The casein family is built up by 
several types of caseins (αS1, αS2, β and 
κ) and each has its own amino acid 
composition, genetic variations, and 
functional properties. [2-8] These proteins are suspended in milk in a complex called a 
micelle.  
 
Fluorescein isothiocyanate (FITC) had been proved as a very useful reagent for attaching 
the fluorescein chromophore to amino groups of proteins for the micro-detection of 
protein in cells under ultraviolet light in the 1960s. [9] [10] It is one kind of base 
fluorescein molecule functionalized with an isothiocyanate reactive group (–N=C=S) at 
one of two hydrogen atoms on the bottom ring of the structure. The excitation wavelength 
is 494 nm and emission wavelength 518 nm.  
 
In 1984, Sally S. Twining developed one kind of assay for proteolyic enzymes using 
FITC labeled casein to yield fluorescein thiocarbamoyl (FTC) derivative. [11] This assay 
for proteases using FTC-casein is very sensitive, inexpensive and reproducible. Basic 
fluorometer can accomplish the detect mission. By reason of so much advantage, this 
assay was applied widely. In 1997 Dong Ryul Lee with others mentioned that 
FITC-casein was introduced to assess the changes in the structure of the zona pellucid 
 
Fig. 1. Fluorescein isothiocyanate (FITC) 
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structure of embryos which had been cultured in human tubal fluid medium with pronase 
and proteinase K. [12] In the same year, Quesada, A. R. et al. proved FITC-casein assay 
can be applied to measure matrix metalloproteinase (MMP) activity and they suggested 
the this inexpensive assay was the method of choice for the screening of inhibitors of 
stromelysin, matrilysin and gelatinase A, it was very suitable for high throughput 
screening of MMP inhibitors. [13] In the cheese-making industry milk-clotting proteases 
are widely used, these proteases are enzymes that use soluble caseins as their preferential 
substrates. In 2006 Ageitos, J. M. with other researchers described FITC-casein assay for 
specific quantification of the activity of the milk-clotting proteases. [14] They got the 
conclusion that the FITC-casein assay allowed a precise screening of the enzymatic phase 
during the milk coagulation process; it is amenable to use by the cheese-making industry 
for specifically testing caseinolytic enzymes of different origin and nature.  
 
By the widely usage of this assay, it was be prepared as “Protease Fluorescent Detection 
Kit” which is easy-to-use kit to detect trace amounts of protease or determine total 
protease activity by many companies such as Sigma-aldrich, Marker Gene and Neogen 
Corporation. These kits had been used to test thousands of samples for proteolytic 
activity. 
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Fig. 2. The protease fluorescent detection kit (Sigma, product code PF0100) 
 
Here the author summarizes the excellence of FITC casein assay. First is fast, to label just 
take about one hour. Secondly it is one amine-specific labeling. Optimized procedure 
following the standard protocol results in antibodies with excellent dye: protein ratios for 
optimum activity and fluorescence. Single-use fluors-no need to weigh tiny amounts of 
powder; kits contain single-use vials of reagent. Efficient purification kits include 
purification resin and easy-to-use spin columns, ensuring rapid and efficient removal of 
non-reacted dye and excellent protein recovery. 
 
1-3 Ester substrate 
 
Here the author simply describes some esters which are synthesized and explored as 
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substrates for the assay.  
 
1-3-1 p-Nitrophenyl ester 
 
Early in the 1950s the enzymic hydrolysis of certain p-nitrophenyl esters had been 
investigated by scientists form University of Leeds, Hartley, B. S. and Kilby, B. A. [15] 
[16] Diethyl p-nitrophenyl phosphate 1, p-nitrophenyl ethyl carbonate 2 and 
p-nitrophenyl acetate 3 were applied as a substrate for chymotrypsin. In their experiments 
of measurement of proteolytic activity, during the inhibition by p-nitrophenyl esters, 
nitrophenol is liberated. Because the absorption spectrum of nitrophenol in alkaline 
solution was found to show a peak at 4000A due to the nitrophenolate ion, assay of 
p-nitrophenol according to the optical density at this wavelength was used to estimate 
nitrophenol concentrations by measuring in the quartz cuvette by spectrophotometer.  
 
1-3-2 Benzyl thioester  
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Fig. 3. 1 Diethyl p-nitrophenyl phosphate, 2 p-nitrophenyl ethyl carbonate and 3 
p-nitrophenyl acetate  
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Because the thioester substrates have high susceptibility to enzymatic hydrolysis rates and 
low background hydrolysis rates the peptide thioesters were widely studied to use for the 
active site mapping of numerous serine proteases like trypin and coagulation enzymes. 
[17] [18] One of the studies was carried out by peptide thioester substrates to determine 
the complement serine proteases. [19] They used assay mixtures containing the thiol 
reagent 4,4’-dithiodipyridine at pH 7.5 to measure the rate of thioester hydrolysis. Some 
best substrates for the proteins such as Z-Gly-Leu-Ala-Arg-SBzl and 
Z-Lys-Gly-Gly-Leu-Ala-Arg-SBzl were proved very sensitive and quite useful in kinetic 
and active site studies of the purified enzymes.  
 
To study the substie preferences of granzyme M which is a member of a family of granule 
serine proteases that participate in target cell death initiated by cytotoxic lymphocytes, a 
series of peptide benzyl thioester was synthesized. [20] They observed spectrophoto- 
metrically in the presence of 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB, Ellman’s 
reagent ) which detected the benzyl thiol as it is cleaved form the substrate, the hydrolysis 
could be evaluated. (Fig. 4.) 
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Fig. 4. Hydrolysis of a peptide thiobenzyl ester by granzyme M generates benzyl thiol 
which reacts with DTNB to produce Z-nitro-5-thiobenzoic acid. 
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1-3-3 p-Nitroanilide (pNA) 
 
In the early 1960s, spectrophotometric methods had been widely used for measuring the 
activity of amino-peptidases and for measuring substrate specificity according to the 
hydrolysis of p-nitroanilide (pNA), such as the pNA substrates for subtilisin [20], 
alpha-Chymotrypsin [21] [22] and gama-Glutamyltranspeptidase. [23] were established 
successfully. 
 
1-3-4 -Naphthylamide (NA) 
 
Followed the steps of forerunners and marched onward, beta-naphthylamide was 
introduced to set up effective substrate. The synthetic substrate of L-tyrosine 
beta-naphthylamide could measure tyrosine aminopeptidase activity and this compound 
had been proved was a powerful inhibitor of both tobacco and potato tyramine 
N-hydroxycinnamoyl transferase (THT). [24] Elaine Gasparello-Clemente and Paulo 
Flavio Silveira employed naphthylamide substrates such as Z-Gly-Pro-beta- 
naphthylamide, L-proline-beta-naphthylamide and L-alanine-beta- naphthylamide for 
venom peptidase activities. [25] Here are just some applications mentioned. The usage 
and results are commercially acceptable. [26] [27] 
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1-4 4-methylcoumarin-7-amide (MCA) 
 
This compound 7-amino-4-methylcoumarin 
(AMC), an aminocoumarin laser dye, had been 
observed to produce laser emissions in the 
370-760 nm region. (Fig. 5.) In 1976, Morris 
Zimmerman and his crows reported they used 7-glutarylphenyl- 
alaninamido-4-methylcoumarin as substrate, the release of AMC could be determined 
fluorometrically to assay the activity of chymotrypsin. [28] It was the first time that the 
MCA group was focused as a good substrate. In the next year 1977, this new kind of 
fluorogenic substrate had already used for alpha-thrombin, factor Xa, kallikreins, 
urokinase and plasmin.  [29] They synthesized twenty peptide-4-methylcoumarin 
amides (MCA) as Boc-Val-Pro-Arg-MCA, Boc-Ile-Glu-Gly-Arg-MCA and 
Boc-Ser-Gly-Arg-MCA were found to be specific substrates for individual enzymes. 
Many experiments proved it is useful and sensitive. [30-32] Today, the products of 
MCA substrates had been widely used commercially, the “enzymatic assay of cathepsin 
B” as one Sigma-Aldrich product displayed the charm of this fluorescence compound.  
 
Here we list some MCA-substrates that wildly used in the research (Table 1). 
References are also given in their catalog. [33-54] 
 
Fig. 5. 7-Amino-4-methylcoumarin 
(AMC) 
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Table 1. Some of peptide-MCA substrates from a catalog of Peptide Institute, Inc. 
Compounds Enzyme 
Ac-Asp-Asn-Leu-Asp-MCA Caspase-3 
Ac-Leu-Glu-His-Asp-MCA Caspase-9 
Ac-Lys-Thr-Lys-Gln-Leu-Arg-MCA Hepatocyte Growth Factor-Activtor 
Ala-MCA Aminopeptidase 
Arg-MCA Cathepsin H 
Boc-Ala-Gly-Pro-Arg-MCA rANP Precursor Processing Enzyme 
Boc-Arg-Val-Arg-Arg-MCA Furin 
Boc-Asp(OBzl)-Pro-Arg-MCA -Thrombin 
Boc-Val-Pro-Arg-MCA -Thrombin 
Boc-Gln-Ala-Arg-MCA Trypsin 
Pro-Phe-Arg-MCA Pancreatic / Urinary Kallikrein 
Boc-Glu-Lys-Lys-MCA Plasmin 
Boc-Leu-Ser-Thr-Arg-MCA Activated Protein C 
Boc-Phe-Ser-Arg-MCA Trypsin, Tryptase 
Boc-Val-Leu-Lys-MCA Plasmin and Calpain 
Leu-MCA Aminopeptidase 
Lys-MCA Aminopeptidase 
Suc-Ala-Ala-Ala-MCA Elastase 
Suc-Ala-Ala-Pro-Phe-MCA Chymotrypsin 
Suc-Leu-Leu-Val-Tyr-MCA Chymotrypsin, Calpain 
Z-Ala-Ala-Asn-MCA Legumain 
Z-Gly-Pro-Arg-MCA Cathepsin K 
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1-5 Intramolecularly quenched fluorescent substrates (IQFS) 
 
Right from born it became to one hot research direction naturally. In 1977 Carmel, A. 
and his fellows synthesized one series of fluorogenic oligopeptide derivatives, like 
Lys(Abz)-X-ONBzl (Abz is aminobezoyl(anthraniloyl); ONBzl is p-nitrobenzyloxy), it 
could be hydrolyzed by leucine aminopeptidase. [55] The most interesting part was that 
the hydrolysis was accompanied by an increase in fluorescence due to disruption of the 
intramolecular quenching of the fluorescent anthraniloyl moiety by the nitrobenzyl ester 
group. To put it in simply, it had structure F-XX-Q that F is fluoresce group quenched 
by intramolecular interaction with the group Q. Enzymatic cleavage of the peptide chain 
XX generates the unquenched F-containing derivative and resultant fluorescence was 
used for quantitative hydrolysis rate measurement. It had been believed as one good 
method for fluorescent substrates high-throughput screening for selective inhibitors of 
specific enzyme. [56-60] 
 
1-6 Reference 
 
1. Kunz, C., Lonnerdal, B. American Journal of Clinical Nutrition. 1990. 51 (1), 37–46. 
2. Alexander, L. J., Beattie, C. W. Anim. Genet. 1992. 23, 283–288.  
3. Devinoy, E., Schaerer, E., Jolivet, G., Fontaine, M. L., Kraehenbuhl, J. P., Houdebine, 
L. M. Nucleic Acids Res. 1988. 16, 11813.  
4. Alexander, L. J., Gupta, N. A., Beattie, C. W. Anim. Genet. 1992. 23, 365–367.  
5. Bouniol, C. Gene. 1992. 125, 235–236.  
6. Dumas, B. R., Brignon, G., Grosclaude, F., Mercier, J. C. Eur. J. Biochem. 1972. 25, 
 11 
 
505–514.  
7. Yoshimura, M., Banerjee, M. R., Oka, T. Nucleic Acids Res. 1986. 14, 8224.  
8. Gorodetskii, S.I., Kaledin, A. S. Genetika. 1987. 23, 398–404. 
9. Udenfriend, S. Arch Dermatol. 1963. 87 (2), 283.  
10. Maeda, H., Kawauchi, H. Biochem. Biophys. Res. Commun. 1968. 31, 188. 
11. Twining, S. S. Anal. Biochem. 1984. 143, 30–34. 
12. Lee, D. R., Lee, J. E., Yoon, H. S., Lee, H. -J., Kim, M. K., Roh, S. I. Human 
Reproduction. 1997. 12 (11), 2493-2498. 
13. Quesada, A. R., Barbacid, M. M., Mira, E., Fernández-Resa, P., Márquez, G., Aracil, 
M. Clin. Exp. Metastasis. 1997. 15, 26-32. 
14. Ageitos, J. M. J. Dairy Sci. 2006. 89, 3770-3777. 
15. Hartley, B. S., Kilby, B. A. Biochem J. 1952. 50, 672–678.  
16. Hartley, B. S., Kilby, B. A. Biochem. J. 1954. 56, 288–297. 
17. Power, J. C., Kan, C. M. Methods in Enzymology. 1995. 248, 3-18.  
18. Niwa, N., Yamagishi, Y., Murakami, H., Suga, H. Bioorg. Med. Chem. Lett. 2009. 
19, 3892-3894. 
19. Kam, C. M., McRae, B. J., Harper, J. W., Niemann, M. A., Volanakis, J. E., Powers, 
J. C. J. Bio. Chem. 1987. 262 , 3444-3451. 
20. Rukamp, B. J. Rukamp, B. J., Kam, C. M., Natarajan, S., Bolton, B. W., Smyth, M. 
J., Kelly, J. M., Powers, J. C. Arch. Biochem. Biophys. 2004. 422, 9-22. 
21. Pozsgay, M., Gáspár, Jr. R., Elödi, P. FEBS lett. 1977. 74, 67-70. 
22. Stepanov, V. M., Terent'eva, E. Y., Voyushina, T. L., Gololobov, M. Y. Bioorg. 
Med. Chem. 1995. 3 (5), 479-485. 
23. Lherbet, C., Morin, M., Castonguay, R., Keillor, J. W. Bioorg. Med. Chem. Lett. 
 12 
 
2003. 13, 997-1000. 
24. Negrel, J., Javelle F. Phytochem. 2001. 56, 523-527. 
25. Elaine, G.-C., Silveira, P. F. Toxicon. 2002. 40, 1617-1626. 
26. Xiong, X., Barathi, A., Beuerman, R. W., Tan, D. T. H. J. Chrom. B. 2003. 796, 
63-70. 
27. Cordova, J. C., Kumar, A. Int. J. Antimic. Agen. 2011. 37, 420-424. 
28. Zimerman, M., Yurewicz, E., Patel, G. Anal. Biochem. 1976. 70 (1), 258-262. 
29. Morita, T., Kato, H., Iwanaga, S., Takada, K., Kimura, T. J. Biochem. 1977. 82 (5), 
1495-1498. 
30. Kaga, K. L., Richardson, P. L., Traphagen, L., Severin, J., Pereda-Lopez, A., 
Lubben, T., Davis-Taber, R., Vos, M. H., Bartley, D., Walter, K., Harlan, J., Solomon, 
L., Warrior, U., Holzman, T. F., Faltynek, C., Surowy, C. S., Scott, V. E. J. Neuro. 
Meth. 2007. 161, 47-54. 
31. Ramarao, M. K., Murphy, E.A., Shen, M. W., Wang, Y., Bushell, K. N., Huang. N., 
Pan, N., Williams, C., Clark, J. D. Anal. Biochem. 2005. 343 (1), 143–151. 
32. De Bank, P.A., Kendall, D. A., Alexander, S. P. H. Biochem. Pharmacol. 2005. 69 
(8), 1187–1193. 
33. Tanuma, S., Yoshimori, A., Takasawa, R. Biol. Pharm. Bull. 2004. 27, 968. 
34. Thornberry, N. A., Rano, T. A., Peterson, E. P., Rasper, D. M., Timkey, T., 
Garcia-Calvo, M., Houtzager, V. M., Nordstrom, P. A., Roy, S., Vaillancourt, J. P., 
Chapman, K. T., Nicholson, D. W. J. Biol. Chem. 1997. 272, 17907-17911. 
35. Mizuno, K., Tanoue, Y., Okano, I., Harano, T., Takada, K., Nakamura, T. Res. 
Commun. 1994. 198, 1161.  
36. Mantle, D., Hardy, M. F., Lauffart, B., McDermott, J. R., Smith A. I., Pennington, R. 
 13 
 
J. J. Biochem. 1983. 211, 567-573. 
37. Schwartz, W. N., Barret, A. J. J. Biochem. 1980. 191, 487-497. 
38. Imada, T., Takayanagi, R., Inagami, T. Biochem. Biophy. Res. Commun. 1987. 143, 
587. 
39. Hatsuzawa, K., Murakami, K., Nakayama, K. J. Biochem. 1992. 111, 296-301. 
40. Kawabata, S., Miura, T., Morita, T., Kato, H., Fujikawa, K., Iwanaga, S., Takada, K., 
Kimura, T., Sakakibara, S. Eur. J. Biochem. 1988. 172, 17-25. 
41. Lottenberg, R., Christensen, U., Jackson, C. M., Coleman, P. L. Proteolytic 
Enzymes Part C. 1981. 80, 341. 
42. Mizuno, K., Nakamura, T., Tanada, K., Sakakibara, S., Matsuo, H. Biochem. Biophy. 
Res. Commun. 1987. 144, 807. 
43. Oh-ishi, S., Katori, M. Thromb. Res. 1979. 14, 551. 
44. Kato, H., Adachi, N., Ohno, Y., Iwanaga, S., Takada, K., Sakakibara, S. J. Biochem. 
1980. 88, 183-190. 
45. Ohno, Y., Kato, H., Morita, T., Iwanaga, S., Takada, K., Sakakibara, S., Stenflo, J. J. 
Biochem. 1981. 90, 1387-1395. 
46. Muramatsu, M., Itoh, T., Takei, M., Endo, K. Biol. Chem. Hppe-Seyler. 1988. 369, 
617. 
47. Iwanaga, S., Morita, T., Kato, H., Harada, T., Adachi, N., Sugo, T., Maruyama, I., 
Takada, K., Kimura, T., Sakakibara, S. Kinins-2: Biochemistry, Pathophysiology, and 
Clinical Aspects. 1979. 147-163. 
48. Kanaoka, Y., Takahashi, T., Nakayama, H. Chem. Pharm. Bull. 1977. 25, 362-363. 
49. Saifuku, K., Sekine, T., Namihisa, T., Takahashi, T., Kanaoka, Y. Clin. Chim. Acta. 
1978. 84, 85. 
 14 
 
50. Sawada, H., Yokosawa, H., Hoshi, M., Ishii, S. Experientia. 1983. 39. 377. 
51. Sasaki, T., Kikuchi, T., Yumoto, N., Yoshimura, N., Murachi, T. J. Biol. Chem. 
1984. 259,12489-12494. 
52. Chen, J. M., Dando, P. M., Rawlings, N. D., Brown, M. A., Young, N. E., Stevens, 
R. A., Hewitt, E., Watts, C., Barrett, A. J. J. Biol. Chem. 1997.272, 8090-8098. 
53. Billings, P. C., Carew, J. A., Keller-McGandy, C. E., Goldberg, A. L., Kennedy, A. 
R. Proc. Natl. Acad. Sci. U.S.A. 1987. 84, 4801-4805. 
54. Groot, E., Hulstein, J. J., Rison, C. N., de Groot, P. G., Fijnheer, R. J. Thromb. 
Haemost. 2006. 4, 698-699. 
55. Carmel, A., Kessler, E., Yaron, A. Eur. J. Biochem. 1977. 73, 617-625. 
56. Gideon F. G., Dalia G. D., Yaron, A. FEBS Lett. 1981. 135, 131-134. 
57. Poras, H., Ouimet, T., Orng, S. -V., Dangé, E., Fournié-Zaluski, M. –C., Roques, B. 
P. Anal. Biochem. 2011. 419 (2), 95-105. 
58. Mawn, T. M., Popov, A. V., Delikatny, E. J. Anal. Biochem. 2012. 422 (2), 96-102. 
59. Garcia-Echeverria, C., Rich, D. H. FEBS Letts. 1992. 297, 100-102. 
60. Weimera, S., Oertelb, K., Fuchsbauer, H. -L. Anal. Biochem. 2006. 352, 110-119. 
 15 
 
Chapter 2  
 
Fluorescent substrates of histone deacetylases (HDACs) 
 
2-1 Introduction 
 
Histone, which helps the DNA organization in eukaryotic cells, is found in octameric 
form with DNA wrapped around the exterior of the octamer. In the assistant of histone 
proteins, DNA can maintain in a highly ordered and condensed form via its association 
with small, this packaged DNA is termed chromatin and its maintenance is crucial for 
the viability of every cell. The two forms of chromation could be simply explain as 
 
Fig. 1. The packaged DNA termed chromosome in the help of histone proteins.  
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heterochromatin is tightly compacted and highly repressive to DNA processes such as 
gene transcription, whereas euchromatin has a more open conformation an tends to 
support transcription. [1-4] The DNA and histone complexes are called nucleosomes 
which have core histones H2A, H2B, H3 and H4, are packed to from chromation. [5] 
(Fig. 1) The amino termini extend of histone can be modified post-translationally by 
acetylation, phosphorylation and methylation. [6, 8] (Fig. 2) Those modifications may 
affect their charge and function. In those modifications, acetylation and deacetylation 
had been focused on many years and the deacetylation is believed as a target for new 
anticancer drugs. [3, 5, 9, 10]  
 
 
 
 
 
Fig. 3. Reversible acetylation and deacetylation in the association of HAT and HDAC 
(figure provided by University of Illinois at Chicago). 
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The acetylation state of histone tails is controlled by the antagonistic action of two 
enzyme families: histone acetyltransferases (HATs), which transfer an acetyl group from 
acetyl CoA to an -amino group of lysine residues of histones; and histone deacetylases 
(HDACs), which catalyze the hydrolysis of these acetamides. (Fig. 3) [5, 11, 12] The 
abnormal activities of HATs and HDACs have been linked to the pathogenesis of cancer. 
[10, 13-16] It had been reported the inhibiter of HDACs could inhibit cell growth, 
induce terminal differentiation, and suppress tumor growth in the mouse model. [17-22] 
 
Nowadays the most common method use for measuring the activity of HDACs is 
applied as followed: in the medium of cultured cells, add the radioactively acetic acid as 
labeled to radiolabel histone metabolism in the cell; treat these with purified HDACs, 
after the reaction, using ethyl acetate to extract the liberated radiolabeled acetyl groups 
from histones; the enzyme activity could be detected by measuring the radioactivity. [23, 
24] The complicated of this method for measuring HDACs is understood.  
 
 
Fig. 2. The post-translational modifications of histone tails. Ac: Acetylation; Me: 
Methylation; P: Phosphorylation.  
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HDACs, are classified depending on sequence homology to the yeast original enzymes 
and domain organization: HDAC1 was identified using the HDAC inhibitor trapoxin as 
an affinity from nuclear extract in 1996. [23] It was found that HDAC1 shares high 
sequence homology with yeast Rpd3 (Reduced potassium dependency 3), a global gene 
regulator and transcriptional co-repressor with histone deacetylase activity. [24] 
Subsequently, 18 HDAC family members have been identified in the human genome. 
HDACs are divided into class I-IV based on their sequence homology to their yeast 
orthologues Rpd3, HdaI and Sir2 (silent information regulator 2) respectively. [25,26] 
Class I (HDACs 1, 2, 3, and 8) and class II (HDACs 4, 5, 6, 7, 9, and 10) HDACs are 
Zn2+-dependent amidohydrolases with a conserved catalytic core but differing in size, 
domain structure and tissue expression pattern. Class III HDACs are NAD+ dependent, 
unrelated in sequence and mechanism to classes I and II. Class IV consists of HDAC11. 
Very little information is available about its expression and function. [27]  
 
In recent decades, HDAC inhibitors (HDACI) had been focused as targets for cancer 
treatment by expecting their ability to alter several cellular functions known to be 
deregulated in cancer calls. HDACI selectively induces cellular differentiation, growth 
arrest and apoptosis in a broad spectrum of tumor cells without affecting normal cells, 
which contributes to their known low-level of toxicity compared to other anticancer 
agent. [28] In 1990s, Yoshida and coworkers found that three different compounds with 
various functional groups and with different characteristics inhibit HDAC in different 
extents. [17] One of the inhibitors, trichostatin A (TSA), is a strong inhibitor of HDAC. 
Another HDAC inhibitor Ky-2 is also a strong inhibitor as a cyclic tetrapeptide [29].     
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2-2 Target 
 
In modern society, human beings focus their bodies more than the ever, the world pay 
attention to develop the pharmacy and chemistry more than the ever. It makes the 
pharmaceutical companies and researchers promote innovatively, this also makes a large 
number of candidate compounds produced. It must be developed that the efficiency and 
useful substances for exploring drugs, this is the growing demand for a more convenient 
method of measuring. Because the common assay method for HDACs is still 
complicated, the author aimed to establish one kind of efficient and sensitively assay 
substrates that will be described as followed. 
 
2-3 Design 
 
Peptide-Lys(X)-MCA
Peptide-Lys-MCA + X-OH                 
Histone deacetylases 
(HDACs)
Peptide + AMC                 
trypsin
 
Fig. 4. The principle of HDAC activity measurement using peptide-MCA. 
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The measuring principle using peptide-MCA for HADCs was shown in Fig. 4. In order 
to elucidate the profile of acyl groups, a series of Ac-Lys(X)-MCA (X = Ac, Tf, Py, Pr, 
Pe, Df, Bu, Mp, Pf, Bz, Fo and Ca) compounds have been designed. From the soucse 
like Acetic acid, trifluoroacetic acid, propionic anhydride, propargylic acid, pcryloyl 
chloride, 2,2-difluoropropionic acid, butanoic acid, isobutyric anhydride, 
pentafluoropropionic acid, benzoic acid, formic acid and chloroacetic acid. 
 
 
 
Table 1. Various acyl groups combined to lysine side chain, composition and source. 
Acyl group Composition Source 
Acetyl (Ac) CH3CO- Acetic acid 
Trifluoroacetyl (Tf) CF3CO- Trifluoroacetic acid 
Propionyl (Pr) CH3CH2CO- Propionic anhydride 
Propargylyl (Py) HCCCO- Propargylic acid 
Acryloyl (Pe) CH2=CHCO- Acryloyl chloride 
2,2-Difluoropropionyl (Df) CH3CF2CO- 2,2-Difluoropropionic acid 
Butanoyl (Bu) CH3CH2CH2CO- Butanoic acid 
Isobutyryl (Mp) (CH3)2CHCO- Isobutyric anhydride 
Pentafluoropropionyl (Pf) CF3CF2CO- Pentafluoropropionic acid 
Benzoyl (Bz) PhCO- Benzoic acid 
Formyl (Fo) HCO- Formic acid 
Chloroacetyl (Ca) ClCH2CO- Chloroacetic acid 
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Fig.5. The structure of designed Ac-Lys(X)-MCA. 
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2-4 Experimental 
 
2-4-1 Synthesis of peptide-MCA 
 
General 
 
Unless otherwise noted, all solvents and reagents were reagent grade obtained from 
WAKO, Japan. Flash chromatography was performed using silica gel 60 (230–400 mesh) 
eluting with solvents as indicated. All compounds were routinely checked by thin layer 
chromatography (TLC) and/or high performance liquid chromatography (HPLC). TLC 
was performed on aluminum-backed silica gel plates (Merck DC-Alufolien Kieselgel 60 
F254) with spots visualized by UV light or charring. Analytical HPLC was performed on 
a Hitachi instrument equipped with a chromolith performance RP-18e column (4.6 × 
100 mm, Merck). The mobile phases used were A: H2O with 0.1% TFA, B: CH3CN 
with 0.1% TFA using a solvent gradient of A-B over 15 min with a flow rate of 2 
mL/min, with detection at 220 nm. HR FAB-mass spectra were measured on a JEOL 
JMS-SX 102A instrument. 
 
2-4-1-1 Synthesis of Ac-Lys(X)-MCA  
 
Synthesis of Ac-Lys-MCA.HCl 
 
To a chilled solution or suspension of Fmoc-Lys(Boc)-OH (1.86 g, 4 mmol) in DCM 
(10 mL) was added DCC (0.42 g, 2 mmol). After 1 h reaction in ice bath, AMC (0.36 g, 
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2 mmol) was added to the reaction mixture. The suspension was stirred at room 
temperature overnight. The compound was extracted with AcOEt, washed with 10% 
critic acid, 4% NaHCO3 and brine, MgSO4. Filtration and evaporation of AcOEt gave 
solid compound (1.13 g, 1.8 mmol, yield 90%).  
 
Synthesis of Ac-Lys(Boc)-MCA 
 
Fmoc-Lys(Boc)-MCA (0.65 g, 1.0 mmol) was dissolved in 20% piperidine/DMF (10 
mL) and kept for 30 min at room temperature. After evaporation of piperidine and DMF, 
the residue was extracted with AcOEt, washed with sat. Na2CO3, dried over with 
anhydrous Na2CO3. The solution was concentrated to yield H-Lys(Boc)-MCA (0.4 g, 
1.0 mmol, yield 100%). 
 
Dissolve the compound of H-Lys(Boc)-MCA in 3 mL DMF using ice bath to cool down. 
Added NEt3 (0.6 mmol, 1.1 eq.) and Ac2O (0.6 mmol, 1.1 eq.) to react 2 hours. The 
solution was concentrated and the residues were applied to a silica gel column using a 
mixture of methanol/chloroform (1:99), it gave Ac-Lys(Boc)-MCA (0.83 g, 0.56 mmol, 
yield 100%). 
 
Ac-Lys(Boc)-MCA (0.21 g, 0.28 mmol) was dissolved in 4N HCl/ dioxane (2 mL) and 
kept for 2 h at room temperature. After evaporation of HCl and dioxane, the residue was 
crystallized with ether to yield Ac-Lys-MCA as HCl salt (0.2 g, 0.28 mmol, 100%). 
 
2-4-1-2 Synthesis of Ac-Lys(Ac)-MCA 
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Dissolve Ac-Lys-MCA.HCl in 3 mL DMF using ice bath to cool down. Added NEt3 (0.6 
mmol, 1.1 eq.) and Ac2O (0.6 mmol, 1.1 eq.) to react 2 hours. The solution was 
concentrated and the residues were applied to a silica gel column using a mixture of 
methanol/chloroform (1:99), it gave Ac-Lys(Ac)-MCA (0.83 g, 0.56 mmol, yield 100%). 
HRMS (FAB) m/z found: 388.1899, calcd. for [M+H]+ C20H26N3O5: 388.1872. 
 
2-4-1-3 Synthesis of Ac-Lys(Tf)-MCA 
 
Boc-Lys(Tf)-MCA (200 mg, 0.4 mmol)was dissolved in 4N HCl/ dioxane (2 mL) and 
kept for 2 h at room temperature. After evaporation of HCl and dioxane, the residue was 
crystallized with ether to yield H-Lys(Tf)-MCA as HCl salt (153 mg, 0.36 mmol, 90%). 
 
Dissolve the compound of H-Lys(Tf)-MCA.HCl in 3 mL DMF using ice bath to cool 
down. Added NEt3 (0.54 mmol, 1.1 eq.) and Ac2O (0.54 mmol, 1.1 eq.) to react 2 hours. 
The solution was concentrated and the residues were applied to a silica gel column 
using a mixture of methanol/chloroform (1:99), it gave Ac-Lys(Tf)-MCA (134 mg, 0.31 
mmol, yield 85%). HRMS (FAB) m/z found: 442.1590, calcd. for [M+H]+ 
C20H23N3O5F3: 442.1590. 
 
2-4-1-4 Synthesis of Ac-Lys(Pr)-MCA 
 
To a chilled solution or suspension of propionic anhydride (90 mg, 1.2 mmol) in DCM 
(3 mL) was added DCC (130 mg, 0.6 mmol). After 2 hours reaction in ice bath, 
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Ac-Lys-MCA.HCl (200 mg, 0.5 mmol) and NEt3 (0.14 mL, 1 mmol) were added to the 
reaction mixture. The suspension was stirred at room temperature overnight. The 
solution was concentrated and the residues were applied to a silica gel column using a 
mixture of methanol/chloroform (1:99), it gave Ac-Lys(Pr)-MCA (35 mg, 0.3 mmol, 
yield 25%). HR/MS (FAB) m/z found: 402.2048, calcd. for [M+H]+ C21H28N3O5: 
402.2029. 
 
2-4-1-5 Synthesis of Ac-Lys(Py)-MCA 
 
To a chilled solution or suspension of propargylic acid (98 mg, 1 mmol) in DCM (3 mL) 
was added DCC (130 mg, 0.6 mmol). After 2 hours reaction in ice bath, 
Ac-Lys-MCA.HCl (200 mg, 0.5 mmol) and NEt3 (0.14 mL, 1 mmol) were added to the 
reaction mixture. The suspension was stirred at room temperature overnight. The 
solution was concentrated and the residues were applied to a silica gel column using a 
mixture of methanol/chloroform (1:99), it gave Ac-Lys(Py)-MCA (50 mg, 0.12 mmol, 
yield 24%). HRMS (FAB) m/z found: 398.1742, calcd. for [M+H]+ C21H24N3O5: 
398.1716. 
 
2-4-1-6 Synthesis of Ac-Lys(Pe)-MCA 
 
To a chilled solution or suspension of acryloyl chloride (67 mg, 0.72 mmol) in pyridine 
(3 mL), Ac-Lys-MCA.HCl (230 mg, 0.6 mmol) and NEt3 (0.1 mL, 0.72 mmol) were 
added to the reaction mixture. The suspension was stirred at room temperature 
overnight. The solution was concentrated and the residues were applied to a silica gel 
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column using a mixture of methanol/chloroform (1:99), it gave pure Ac-Lys(Pe)-MCA 
(15 mg, 0.1 mmol, yield 17%). HRMS (FAB) m/z found: 400.1935, calcd. for [M+H]+ 
C21H26N3O5: 400.1872. 
 
2-4-1-7 Synthesis of Ac-Lys(Df)-MCA 
 
2,2-Difluoropropionic acid (34 mg, 0.31 mmol) and Ac-Lys-MCA.HCl (100 mg, 0.26 
mmol) were dissolved in 3 mL DMF. To this chilled solution, HOBt.H2O (48 mg, 0.31 
mmol, 1.1 eq.), HBTU (118 mg, 31 mmol, 1.1 eq.) and DIEA (0.14 mL, 0.1 mmol, 1.1 
eq.) were added. The solution was concentrated and the residues was extracted with 
AcOEt, washed with 10% critic acid, 4% NaHCO3 and brine, dried over MgSO4. 
Filtration and evaporation of AcOEt, the residues were applied to a silica gel column 
using a mixture of methanol/chloroform (1:99), it gave Ac-Lys(Tf)-MCA (51 mg, 0.11 
mmol, yield 43%). HRMS (FAB) m/z found: 438.1889, calcd. for [M+H]+ 
C21H26N3O5F2: 438.1841. 
 
2-4-1-8 Synthesis of Ac-Lys(Bu)-MCA 
 
Butanoic acid (14 mg, 0.16 mmol) and Ac-Lys-MCA.HCl (50 mg, 0.13 mmol) were 
dissolved in 1 mL DMF. To this chilled solution, HOBt.H2O (23 mg, 0.16 mmol, 1.2 
eq.), DCC (41 mg, 0.2 mmol, 1.5 eq.) and NEt3 (0.02 mL, 0.15 mmol, 1.2 eq.) were 
added. The solution was concentrated and the residues was extracted with AcOEt, 
washed with 10% critic acid, 4% NaHCO3 and brine, dried over MgSO4. Filtration and 
evaporation of AcOEt, the residues were applied to a silica gel column using a mixture 
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of methanol/chloroform (1:99), it gave Ac-Lys(Tf)-MCA (38 mg, 0.01 mmol, yield 
70%). HRMS (FAB) m/z found: 416.2209, calcd. for [M+H]+ C22H30N3O5: 416.2185. 
 
2-4-1-9 Synthesis of Ac-Lys(Mp)-MCA 
 
To a chilled solution or suspension of isobutyric anhydride (31 mg, 0.03 mmol) in 
pyridine (2 mL) Ac-Lys-MCA.HCl (50 mg, 0.13 mmol) was added in ice bath. The 
suspension was stirred at room temperature overnight. The solution was concentrated 
and the residues were applied to a silica gel column using a mixture of 
methanol/chloroform (1:99), it gave Ac-Lys(Tf)-MCA (39 mg, 0.09 mmol, yield 71%). 
HRMS (FAB) m/z found: 416.2156, calcd for [M+H]+ C22H30N3O5: 416.2185. 
 
2-4-1-10 Synthesis of Ac-Lys(Pf)-MCA 
 
To a chilled solution or suspension of pentafluoropropionic acid (62 mg, 0.19 mmol) in 
DCM (3 mL) was added DCC (20 mg, 0.1 mmol). After 2 hours reaction in ice bath, 
Ac-Lys-MCA.HCl (60 mg, 0.16 mmol) and NEt3 (0.05 mL, 0.32 mmol) were added to 
the reaction mixture. The suspension was stirred at room temperature 1 hour. The 
solution was concentrated and the residues were applied to a silica gel column using a 
mixture of methanol/chloroform (1:99), it gave pure Ac-Lys(Pf)-MCA (40 mg, 0.1 
mmol, yield 68%). HRMS (FAB) m/z found: 492.1516, calcd. for [M+H]+ C21H23N3O5: 
492.1558. 
 
2-4-1-11 Synthesis of Ac-Lys(Bz)-MCA 
 28 
 
 
Benzoic acid (25 mg, 0.2 mmol) and Ac-Lys-MCA.HCl (55 mg, 0.16 mmol) were 
dissolved in 1 mL DMF. To this chilled solution, HOBt.H2O (24 mg, 0.16 mmol, 1.2 
eq.), DCC (41 mg, 0.2 mmol, 1.5 eq.) and NEt3 (0.02 mL, 0.15 mmol, 1.2 eq.) were 
added. The solution was concentrated and the residues was extracted with AcOEt, 
washed with 10% critic acid, 4% NaHCO3 and brine, dried over MgSO4. Filtration and 
evaporation of AcOEt, the residues were applied to a silica gel column using a mixture 
of methanol/chloroform (1:99), it gave Ac-Lys(Bz)-MCA (49 mg, 0.12 mmol, yield 
76%). HRMS (FAB) m/z found: 450.2023, calcd. for [M+H]+ C25H28N3O5: 450.2029. 
 
2-4-1-12 Synthesis of Ac-Lys(Fo)-MCA 
 
Formic acid (0.012 mL, 0.28 mmol) and Ac-Lys-MCA.HCl (100 mg, 0.26 mmol) were 
dissolved in 1 mL DMF. To this chilled solution, HOBt.H2O (47 mg, 0.31 mmol, 1.2 
eq.), HBTU (163 mg, 0.31 mmol, 1.2 eq.) and DIEA (0.13 mL, 0.52 mmol, 2 eq.) were 
added. The solution was concentrated and the residues was extracted with AcOEt, 
washed with 10% critic acid, 4% NaHCO3 and brine, dried over MgSO4. Filtration and 
evaporation of AcOEt, the residues were applied to a silica gel column using a mixture 
of methanol/chloroform (1:99), it gave Ac-Lys(Fo)-MCA (31 mg, 0.11 mmol, yield 
39%). HRMS (FAB) m/z found: 374.1637, calcd for [M+H]+ C19H24N3O5: 374.1716. 
 
2-4-1-13 Synthesis of Ac-Lys(Ca)-MCA 
 
To a chilled solution or suspension of chloroacetic acid (62 mg, 0.65 mmol) in DCM (2 
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mL) was added DCC (69 mg,0.33 mmol). After 2 hours reaction in ice bath, 
Ac-Lys-MCA.HCl (100 mg, 0.26 mmol) and NEt3 (0.09 mL, 0.65 mmol) were added to 
the reaction mixture. The suspension was stirred at room temperature overnight. The 
solution was concentrated and the residues were applied to a silica gel column using a 
mixture of methanol/chloroform (1:99), it gave Ac-Lys(Ca)-MCA (42 mg, 0.13 mmol, 
yield 51%). HRMS (FAB) m/z found: 422.1447, calcd. for [M+H]+ C20H25N3O5Cl: 
422.1483. 
 
2-4-1-14 Synthesis of cortactin substrate Ac-KGFGGK(Ac)-MCA 
 
To a chilled solution or suspension of Fmoc-Lys(Boc)-OH (1.86 g, 4 mmol) in DCM 
(10 mL) was added DCC (0.42 g, 2 mmol). After 1 hr reaction in ice bath, AMC (0.36 g, 
2 mmol) was added to the reaction mixture. The suspension was stirred at room 
temperature overnight. The compound was extracted with AcOEt, washed with 10% 
critic acid, 4% NaHCO3 and brine, MgSO4. Filtration and evaporation of AcOEt gave 
solid compound (1.13 g, 1.8 mmol, yield 90%).  
 
Fmoc-Lys(Boc)-MCA (0.65 g, 1.0 mmol) was dissolved in 20% piperidine/DMF (10 
mL) and kept for 30 min at room temperature. After evaporation of piperidine and DMF, 
the residue was extracted with AcOEt, washed with sat. Na2CO3, dried over with 
anhydrous Na2CO3. The solution was concentrated to yield H-Lys(Boc)-MCA (0.4 g, 
1.0 mmol, yield 100%). 
 
Fmoc-Lys(Boc)-MCA (0.21 g, 0.28 mmol) was dissolved in 4N HCl/ dioxane (2 mL) 
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and kept for 2 h at room temperature. After evaporation of HCl and dioxane, the residue 
was crystallized with ether to yield Ac-Lys-MCA as HCl salt (0.2 g, 0.28 mmol, 100%). 
 
Dissolve Fmoc-Lys-MCA.HCl in 3 mL DMF using ice bath to cool down. Added NEt3 
(0.3 mmol, 1.1 eq.) and Ac2O (0.3 mmol, 1.1 eq.) to react 2 hours. The solution was 
concentrated and the residues were applied to a silica gel column using a mixture of 
methanol/chloroform (1:99), it gave Fmoc-Lys(Ac)-MCA (0.16 g, 0.28 mmol, 100%). 
 
The protected peptide Ac-Lys(Boc)-Gly-Phe-Gly-Gly-OH was prepared by assembling 
on Barlos resin by peptide synthesizer, acetylation at the N-terminal with Ac2O (AcOH 
0.25 mmol, NEt3 0.25 mmol, 2 h), and subsequent cleavage from the resin. This 
fragment (133 mg, 0.22 mmol) and H-Lys(Ac)-MCA (86 mg, 0.23 mmol) were 
condensed by the aid of HBTU (90 mg, 0.23 mmol), HOBt･H2O (36 mg, 0.23 mmol) 
and DIEA (0.04 mL, 0.23 mmol) in DMF for 2 h. The product was extracted into AcOEt. 
The work-up afforded Ac-Lys(Boc)-Gly-Phe-Gly-Gly-Lys(Ac)-MCA as white solid 
(186 mg, 90%). Deprotection of this final precursor (86 mg) in TFA and purification by 
Sephadex G-25 column with 10% AcOH, and lyophilization gave 35 mg of 
Ac-KGFGGK(Ac)-MCA_AcOH. LCMS m/z found: 833.4, calcd. for [M+H]+ 
C41H55N9O10: 833.4. 
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2-4-2 Assay 
 
2-4-2-1 Substrate specificity of HDACs 
 
This part of experiment was carried out by the group of RIKEN. Susceptibilities of 
Ac-Lys(X)-MCAs to HDACs were examined in the following conditions. Nine L of 
HDAC buffer and 1.0 L of inhibitor were mixed and then incubated at room 
temperature for 10 min. Then, 10 L of Ac-Lys(C)-MCA solution (100 M) was added 
thereto, which was then incubated at 37oC for 30 min. Thereafter, 20 L of a trypsin 
solution (20 mg/mL) was added thereto, followed by incubation at 37oC for 15 min. 
Then, the fluorescence intensity of the solution was measured at ex 370 nm /em 460 
nm. 
 
Susceptibilities of Ac-Lys(X)-MCAs to SIRTs were examined in the following 
conditions. Nine L of SIRTs assay buffer and 1 L of inhibitor solution were mixed 
and then incubated at room temperature for 10 min. Then, 10 L of a Ac-Lys(X)-MCA 
solution (100 M) were added thereto, which was then incubated at 37oC for 60 min. 
Thereafter, 20 L of a trypsin solution (20 mg/mL) was added thereto, followed by 
incubation at 37oC for 15 min. Then, the fluorescence intensity of the solution was 
measured at ex 370 nm /em 460 nm. 
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2-4-2-2 Measurement of HDAC activity using the substrate 
Ac-KGFGGK(Ac)-MCA  
 
This part of experiment was carried out by the group of RIKEN. Oocytes and embryos 
were collected after removing zona pellucida using ATS and washed using 0.1% 
PBS–PVA. These were frozen in liquid nitrogen and preserved at -150oC until they were 
used. These samples were lysed in a buffer containing 20 mM Tris–HCl (pH 8.0), 150 
mM NaCl, 10% glycerol, and 0.5% NP-40 and incubated on ice for 15 min. Next, the 
substrate was added to these and incubate d at 37oC for 1 h. The substrates used were 
MCA-fused with a cortactin peptide (Ac-KGFGGK(Ac)-MCA). Then, 20 mg/ml 
Trypsin was added to these and incubated at 37oC for 15 min. These samples were 
transferred to a 96-well black plate and measured by excitation 380 nm, emission 460 
nm. [29, 30] 
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2-5 Results and discussion 
2-5-1 Synthesis results 
We successfully synthesized the desired compounds. All compounds were confirmed by 
HRMS (FAB) (Table 2).  
 
 
Table 2. HRMS (FAB) confirmations of desired Ac-Lys(X)-MCA. 
Sequence Composition 
HRMS (FAB) 
Found Calcd. [M+H]+ 
Ac-Lys(Ac)-MCA  C20H25N3O5 387.1787 387.1809 
Ac-Lys(Tf)-MCA  C20H22F3N3O5 441.1601 441.1567 
Ac-Lys(Py)-MCA  C21H27N3O5 401.1971 401.2023 
Ac-Lys(Pr)-MCA  C21H23N3O5 397.1975 397.1645 
Ac-Lys(Pe)-MCA  C21H25N3O5 399.1796 399.1808 
Ac-Lys(Df)-MCA  C21H25F2N3O5 437.1865 437.1836 
Ac-Lys(Bu)-MCA  C22H29N3O5 415.2097 415.2102 
Ac-Lys(Mp)-MCA  C22H29N3O5 415.1905 415.2129 
Ac-Lys(Pf)-MCA  C21H22F5N3O5 491.1201 491.1534 
Ac-Lys(Bz)-MCA  C25H27N3O5 449.1976 449.2012 
Ac-Lys(Fo)-MCA  C19H23N3O5 373.1432 373.1643 
Ac-Lys(Ca)-MCA  C20H24NCl3O5 421.1321 421.1421 
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2-5-2 Profiling of HDACs activities toward Ac-Lys(X)-MCA 
All of the fluorescent compounds in table 1 were subjected to the following HDACs. 
Class I: HDAC1, HDAC3, and HDAC8; class IIA: HDAC4 and HDAC5; class IIB: 
HDAC6 and HDAC10; class III: SIRT1 – SIRT6; class IV: HDAC11 at RIKEN by 
collaboration with Yoshida group. The results will be published elsewhere.  
2-5-3 HDAC activities of MII and the activated oocytes 
 
HDAC activities of MII and the activated oocytes were measured using the substrate 
Ac-KGFGGK(Ac)-MCA, in which peptide sequence is taken from contactin. Activated 
oocytes (PG) showed a signiﬁcant reduction in the HDAC activity which further 
decreased under TSA (Fig. 6). It showed that oocyte-activation achieves upregulation of 
lysine acetylation apparently by reduction of HDAC activities. 
 
 
 
 
Fig. 6. Different HDAC activities between unactivated and activated oocytes. 
 35 
 
2-6 Reference 
 
1. Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., Richmond, T. J. Nature. 
1997. 389, 251-260.  
2. Turner, B. M. Cell. 1993. 75, 5-8.  
3. Zhang, W., Bieker, J. Proc. Natl. Acad. Sci. USA 1998. 95, 9855.  
4. Spotswood, H. T., Turner, B. M. J. Clin. Invest. 2002. 110, 577. 
5. Jenuwein, T., Allis, C. D. Science. 2001. 293, 1074. 
6. Kristeleit, R., Stimson, L., Workman, P., Aherne, W. Expert Opin. Emerg. Drugs. 
2004. 9, 135. 
7. Bannister, A. J., Scheneider, L., Kouzarides, T. Cell. 2002. 109, 801.  
8. Carmena, M., Earnshaw, W. C. Nat. Rev. Mol. Cell Biol. 2003. 4, 842. 
9. Taunton, J., Hassig, C. A., Schreiber, S. L. Science. 1996. 272, 408-411.  
10. Timmermann, S., Lehrmann, H., Polesskaya, A., Harel-Bellan, A. Cell Mol. Life Sci. 
2001. 58, 728. 
11. Jenuwein, T., Smith, M. M. Curr. Opin. Genet. Dev. 2003. 13, 154-160.  
12. Johnstone, R. W. Nat. Rev. Drug Discov. 2002. 1, 287-299. 
13. Crsee, W. D., Seto, E. J. Cell Physiol. 2000. 184, 1-16.  
14. Gregory, P. D., Wangner, K., Horz, W. Exp. Cell Res. 2001. 265, 195-202.  
15. Deckert, J., Struhl, K. Cell Biol. 2001. 70, 81-120.  
16. Gay, G. G., Ekstrom, T. J. exp. Cell Res. 2001. 262, 75-83] 
17. Yoshida, M., Horinouchi, S., Beppu, T. BioEssays. 1995. 17, 423-430.  
18. Richon, V. M., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L., Civoli, F., 
Breslow, R., Rifkind, R. A., Marks, P. A. Proc. Natl. Acad. Sci. USA. 1996. 93, 
 36 
 
5705-5708.  
19. Desai, D., El-Bayoumy, K., Amin, S. Proc. AACR. 1999. 40, 2396, 362.  
20. Dhordain, P., Lin, R. J., Quief, S., Lantoine, D., Kerckaert, J. P., Evans, R. M., 
Albagli, O. Nucleic Acids Res. 1998. 26, 4645.  
21. Amann, J. M., Nip, J., Strom, D. K., Lutterbach, B. Harada, H., Lenny, N., 
Downing, J. R., Meyers, S., Hiebert, S.W. Mol. Cell Biol. 2001. 21, 6470.  
22. Davind, G., Alland, L., Hong, S. H., Wong, C. W., DePinho, R. A., Dejean, A. 
Oncogene. 1998. 16, 2449. 
23. Taunton, J.; Hassig, C. A.; Schreiber, S. L.; Science, 1996, 272, 408-411. 
24. Rundlett, S. E.; Carmen, A. A.; Kobayashi, R.; Bavikin, S.; Turner, B. M.; 
Grunstein, M. Proc. Natl. Acad. Sci. USA, 1996, 93, 14503-14508. 
25. De Ruijter, A. J.; Van Gennip, A. H.; Caron, H. N.; Kemp, S.; van Kuilenburg, A. B. 
Biochem. J. 2003, 370, 737-749. 
26. Gregoretti, I. V.; Lee, Y. M.; Goodson, H. V.; J. Mol. Biol. 2004, 338, 17-31. 
27. Witt, O.; Hedgwig, E. D.; Milde, T.; Oehme, I. Cancer Letters, 2009, 277, 8-21. 
28. Marks, P. A.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.; Kelly, W. K. 
Nat. Rev. Cancer 2001, 1, 194. 
29. Bhuiyan, M. P.; Kato, T.; Okauchi, T.; Nishino, N.; Maeda, S.; Nishino, T. G.; 
Yoshida, M. Bioorg. Med. Chem. 2006, 14, 3438-3446. 
30. Matsubara, K.; Lee, A. R.; Kishigami, S.; Ito, A.; Matsumoto, K.; Chi, H.; Nishino, 
N.; Yoshida, M.; Hosoi, Y. Biochem. Biophys. Res. Commun. 2013, 434, 1-7. 
 
 37 
 
Chapter 3 
 
Synthesis of useful amino acid derivatives for methylated 
peptides 
 
3-1 Introduction 
 
According to the introduction of histone in chapter 2, now the author focuses on the 
methylated modification. As the post-translational modification of histones, methylation 
can be found at the N-terminal peptide chain of the histone octamer. Histone 
methylation was first discovered more than fouty years ago, but even until quite recently, 
there still has a huge surge in our understanding of how methylation of nucleosomal 
histones at specific lysine or arginine residues affects chromatin conformations and 
either facilitates or inhibits transcription from neighboring genes. With the efforts of 
scientists, great progress had been made to understand enzymes that modify histone 
lysine residues have been correlated with a variety of human diseases including arthritis, 
cancer, heart disease, diabetes, and neurodegenerative disorders. It appears that the 
responsible methyltransferases can be targeted in some cases to specific genes and in 
other cases to broader regions of euchromatin or heterochromatin. In order to elucidate 
the specific biological function of different state of lysine methylation, site-specifically 
methylated peptides and full-length histones are necessary to be synthesized. (Fig. 1) 
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It has been studied that the transition between mono-, di-, and trimethylation may 
control transcriptional regulation, RNA maturation, DNA repair and genomic imprinting 
[7-9]. For the elucidation of the specific biological function of different state of lysine 
methylation, the preparation of site-specifically methylated model to mimic histone 
called for the synthesis of N-methyl-L-lysine derivatives urgently. In recent years, the 
developments of synthesis provided some methods to prepare N-methylated amino 
acids and their derivatives. However, these methods are poor in the preparation of 
methylated lysine at –position, and achievement of selectivity for mono-, di-, and 
trimethylated lysine [1-4]. But some impressive progresses in the synthetic strategy of 
N-methyl-L-lysine were also succeeded. Benoiton obtained N-methyl-L-lysine by the 
formaldehyde-formic acid methylation of N-carbobenzoxy-N-benzyl-L-lysine. The 
direct methylation of N-Fmoc-lysine was also developed by reductive methylation with 
formaldehyde and sodium cyanoborohydride and quarternization with excess amount of 
methyl iodide [5, 6]. The earlier methods are costly and no large scale synthesis is 
 
Fig. 1. The mechanism of histone methylation. 
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shown. Herein, we describe a different methodology from the past to prepare 
N-methyl-L-lysine derivatives. In this strategy, protected 2-amino-6-bromohexanoic 
acid (Ab6) has been employed. Our group has reported before the use of derivatives of 
2-amino-n-bromo-alkanoic acid (Abn) as intermediates of functional amino acids 
[10-12]. 
 
Lysine methylation occored on H3 can be found in mono-, di-, or trimethylation state in 
vivo. The model peptides containing Lys(Me)n, where n = 1, 2, and 3 may be useful tool 
in the study of dynamic regulation of genes. In order to prepare Lys(Me)n derivatives 
suitable in peptide synthesis, protected 2-amino-6-bromohexanoic acid (Ab6) has been 
employed. In our lab, the use of derivatives of 2-amino-n-bromo-alakanoic acid (Abn) 
as intermediates of functional amino acids has widely used. By reacting mono-, di-, and 
trimethylamines to protected Ab6, useful Lys(Me)n derivatives such as 
Fmoc-Lys(Me,Boc)-OH have been conveniently prepared. Since methylation of histone 
H3 protein often observed at 4- and 9-positions, H3 peptide (1-12) variously containing 
Lys(Me) have been also synthesized by standard solid phase method. The methylated 
histone peptides were further subjected to the action of trypsin and lysyl endopeptidase. 
As a result, we observed that these peptides were hardly hydrolysed at Lys(Me).  
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3-2 Experimental 
 
3-2-1 Synthesis of amino acid derivatives 
 
3-2-1-1 Synthesis of Fmoc-L-Lys(Me, Boc)-OH 
 
The synthesis started with commercially available diethyl. 1,4-dibromobutane was 
coupled with acetamidomalonate in the presence of sodium ethoxide in absolute 
ethanol.  
 
 
Synthesis of Ac-DL-Ab6-OEt  
 
To a solution of NaOEt (0.95 eq., 95 mmol, 2.23 g) in absolute EtOH (100 mL) was 
added diethyl acetamidomalonate (21.7 g, 100 mL). After the mixture was refluxed for 
30 min, 1, 4-dibromobutane (64.2 g, 300 mmol) was added and reacted for 6 hr under 
 
Scheme 1. Synthesis of Fmoc-L-Lys(Me, Boc)-OH 
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reflux. The solvent and excess dibromobutane were removed by evaporation and the 
product was extracted to ether. Working up gave 35.5 g of product. 
 
The malonate synthesis product was dissolved in EtOH (100 mL) and reacted with 1 M 
NaOH (100 mL) for semi-saponification. The product, half acid-half ester was isolated 
as a solid. The half acid was dissolved in toluene (100 mL) and the solution was 
refluxed for 7 hr for decarboxylation. The removal of solvent remained an oil, which 
was purified by silica gel chromatography (SGC, hexane/AcOEt, 2/1-1/3). Yield of a 
colorless oil; 15.5 g (55%). 
 
Synthesis of Ac-DL-Lys(Me, Boc)-OEt 
 
To a solution of Ac-DL-Ab6-OEt (14.1 g, 50 mmol) in DMF (50 mL), KI (50 mmol, 8.3 
g) was dissolved and then added MeNH2 in MeOH (9 M, 55 mL, 500 mmol) and the 
mixture was allowed to stand for 30 min at room temperature. Solvents and excess 
MeNH2 were removed by evaporation in vacuo to remain a syrup which was dissolved 
in dioxane (50 mL) and added DIEA (17.5 mL, 100 mmol). The removal of MeNH2 
during the concentration of the solution was theus carried out.  
 
Ac-DL-Lys(Me)-OEt in the remaining syrup was again dissolve in dioxane (100 mL) 
and reacted with Boc2O (13.10 g, 60 mmol) at room temperature in the presence of an 
equivalent of DIEA (8.75 mL, 50 mmol) overnight. The desired product was extracted 
into AcOEt (150 mL), the solution being washed with 10% citric acid and 4% NaHCO3, 
subsequently and dried over anhydrous MgSO4. Fltration and concentration of the oil, 
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which was passed through a silica gel column with hexane/ethyl acetate (1/4) gave 15.8 
g (86%) of product. TLC; Rf, 0.66 (chloroform/MeOH, 9/1, v/v).  
 
Synthesis of Ac-DL-Lys(Me, Boc)-OH 
 
Ac-DL-Lys(Me, Boc)-Oet (15.8 g, 48 mmol) was dissolved in EtOH and flashed once 
to remove AcOEt in the oily starting material. To the solution of the ester in EtOH (100 
mL) was added 2 M NaOH (36 mL). After 2 hr, the reaction mixture was acidified with 
AcOH (100 mmol, 5.72 mL) and concentrated to remain an oil. Working up gave 14.5 g 
(100%) of crude product. 
 
Synthesis of L-Lys(Me, Boc) by resolution with aminoacylase 
 
To the oil (14.5 g, 48 mmol), water (240 mL) was added and pH was adjusted to 7 by 
1M NaOH at 38 centgre. To this neutral soltion of aspergillus genus (amino accylase 
1,1.2 g) obtained from TCI, Tokyo, Japan was added. After 20 hr, the reaction mixture 
was concentrated to 100 mL. No preciptitate of L-Lys(Me, Boc) was observed. Then 
recovery of Ac-D-Lys(Me, Boc)-OH. The raction mixture was then acidified with HCl 
to make pH around 2 and Ac-D-Lys(Me, Boc)-OH was extracted with AcOEt (100 mL) 
and washed with brine and dried over MgSO4. After filtration and evaporation of AcOEt, 
the compound was crystallized in ether/pet. ether (1/4) and obtained 5.14 g (70%) of 
product. 
 
Synthesis of Fmoc-L-Lys(Me, Boc)-OH 
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To the aqueous solution (pH about 2) containing Lys(Me, Boc), 10% Na2CO3 (6 eq., 
144 mmol, 15.3 g) and dioxane (200 mL) were added and allowed to react with 
Fmoc-OSu at pH around 10 overnight with stirring at room temp. After evaporation of 
dioxane, the reaction mixture was washed with ether (100 mL) and acidified with HCl 
to make pH 3. The desired compound was extracted with AcOEt (100 mL), washed with 
brine and dried over MgSO4. Filtration and evaporation of AcOEt gave an oil which was 
passed through a silica gel column with chloroform/methanol (49/1) to give the product. 
 
3-2-1-2. Synthesis of Fmoc-L-Lys(Me)2-OH 
 
In the same way, Fmoc-L-Lys(Me)2-OH has been produced starting with diethyl 
(Boc-amino)malonate and using (Me)2NH.HCl as methylating agent. 
 
Synthesis of Boc-DL-Ab6-OEt   
 
 
Scheme 2. Synthesis of Fmoc-L-Lys(Me)2-OH. 
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Cut sodium metal (0.95 eq., 95 mmol, 2.23 g), dissolved completely in EtOH solution 
(100 mL), add diethylacetamidomalonate (1 eq., 100 mmol, 21.72 g) at the temperature 
100 centigrade, then cool down to room temperature. Add 1,4-dibromobutane (3 eq., 
300 mmol, 64.17 g), react 6 hours, evaporate EtOH and separate unreact 
1,4-dibromobutane.  
 
Add Et2O (100 mL), wash with water (100 mL) then evaporate. Add EtOH (100 mL), 
ice bath. Add NaOH (1 eq., 100 mmol) 5 times (each time 20 mL) in 100 minutes. Wash 
with ether, add solid citric acid to make the pH = 3, add AcOEt. After that wash with 
brine 3 times, dry with MgSO4, filtrate. Evaporate the AcOEt. 
 
Add toluene (60 mL), at 135 centigrade react 4.5 hours then check TLC, find the 
reaction is complete. After cool down to room temperature, evaporate the toluene. 
Recovery 17.5 g, 52 mmol (71%). Purity 100%,  Rt: 6.77 min.  
 
Synthesis of Boc-L-Ab6-OH  
 
Boc-DL-Ab6-OEt (17.5 g, 52 mmol), dissolve in DMF (52 mL), add H2O (156 ml), 
keep in 38 centigrade water bath. Add 1M NH3 to pH = 7. Add subtlision 52 mg, at the 
same time add NH3 maintain around pH 6.5~7, 3 hr. Adjust pH = 8, extract 
Boc-D-Ab6-OEt by ether. Add solid citric acid to make pH = 3, extract with AcOEt, 
wash with Brine, dry with MgSO4.  
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Synthesis of Boc-L-Lys(Me)2-OEt  
 
Boc-L-Ab6-OH (11 g, 34 mmol), dissolved in DCM (70 mL) using ice bath, add  
Ethanol (3.06 mL, 1.5 eq.), DCC (10.8 g, 1.5 eq.), DMAP (0.4 g, 0.1 eq.) react 
overnight. Check TLC and HPLC. Evaporated DCM, Wash with 10% citric acid, brine, 
4% NaHCO3, brine. Dry with MgSO4 and filtration. Recovery 7 g, 21 mmol (80%). 
Purity 69%, Rt: 6.43 min.  
 
Synthesis of Fmoc-L-Lys(Me)2-OH 
 
Boc-L-Ab6-OEt (7 g, 21 mmol), dissolved in sp. DMF (21 mL), add KI (3.65 g, 1 eq.), 
(CH)2NH.HCL (5.4 g, 3 eq.), Et3N (10 mL, 3 eq.) react overnight. Evaporated DMF. 
Extracted into AcOEt, washed with sat. Na2CO3. Dry with Na2CO3. Recovery 6.6 g, 21 
mmol (100%). Purity 53%, Rt: 4.01 min.  
 
To the aqueous solution (pH about 2) containing Lys(Me)2, 10% Na2CO3 (6 eq.) and 
dioxane  were added and allowed to react with Fmoc-OSu at pH around 10 overnight 
with stirring at room temp. After evaporation of dioxane, the reaction mixture was 
washed with ether (100 mL) and acidified with HCl to make pH 3. The desired 
compound was extracted with AcOEt (100 mL), washed with brine and dried over 
MgSO4. Filtration and evaporation of AcOEt gave an oil which was passed through a 
silica gel column with chloroform/methanol (49/1) to give the product. 
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3-2-2 Synthesis of methylated peptides 
 
3-2-2-1 Automated solid phase peptide synthesis 
 
As an example of the use of Fmoc-L-Lys(Me, Boc)-OH in the automated solid phase 
peptide synthesis, we synthesized H3 (1-12) peptide with monomethylation at 4- and 
9-positons. The protected peptide fragments were assembled on Wang resin 
(substitution 0.7 mmol/g) by peptide synthesizer (Applied Biosystems 433A) using 
Fmoc/piperidine strategies in FastMoc Chemistry at 0.25 mmol scale. HBTU and HOBt
･H2O were used as activating agent. The cleavage and removal of protecting groups 
were carried out by the treatment with TFA containing phenol (5%), thioanisole (5%), 
ethanedithiol (2.5%) and water (5%). The peptides were precipitated by tert-butyl 
methyl ether. The methylated peptide ARTK(Me)QTARK(Me)STG was purified by 
Sephadex G-25 with 10% AcOH and HPLC, analyzed by LCMS (Table 1).  
 
3-2-2-2 Fluorescent peptide-MCAs 
 
To a chilled solution of Fmoc-L-Lys(Me, Boc)-OH (1.9 g, 4 mmol) in DCM (10 mL), 
DCC (0.42 g, 2 mmol) was added. After 1 h on ice bath, AMC (0.36 g, 2 mmol) was 
added to the mixture. The suspension was stirred at room temperature overnight, then 
the product was filtered and washed with methanol. Fmoc-L-Lys(Me, Boc)-MCA was 
obtained as crystalline solid (2.3 g, 90%). Fmoc-L-Lys(Me, Boc)-MCA was synthesized 
as described in the same manner above. Yield, 2.0 g, 92%.  
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Fmoc-L-Lys(Me, Boc)-MCA (160 mg, 0.25 mmol) was dissolved in 20% 
piperidine/DMF (2 mL) at room temperature. After 30 min the reagent and solvent were 
removed by evaporation. The residues were extracted into ethyl acetate, the solution 
being washed with sat. Na2CO3 and dried over anhydrous Na2CO3. The filtrate was 
concentrated to yield L-lys(Me, Boc)-MCA as free amine (104 mg, 0.25 mmol, 100%). 
Fmoc-L-Lys(Me)2-MCA was treated with 20% piperidine in DMF as described above. 
The free amine L-Lys(Me)2-MCA was obtained 82 mg (0.25 mmol, 100%). 
 
The protected peptide Ac-AR(Pmc)T(tBu)-OH was assembled on Barlos resin 
(substitution 0.6 mmol/g) by manual solid phase synthesis using Fmoc/piperidine 
strategies. HBTU and HOBt･H2O were used for condensation. After capping the 
N-terminal with acetic anhydride, the protected peptide was cleaved from the resin in 
DCM containing TFE and AcOH for 2 h. The protected peptide (177 mg, 0.25 mmol) 
was condensed with L-Lys(Me, Boc)-MCA (104 mg, 0.25 mmol) and L-Lys(Me)2-MCA 
(82 mg, 0.25 mmol) by the aid of HBTU/HOBt method, respectively. The protected 
peptide-MCAs were treated with deprotection cocktail by the same procedure as 
described in automated synthesis. The HPLC purified peptide-MCAs (Table 1) were 
analyzed by HRMS (FAB).  
 
 
Table 1 Mass spectrum data and HPLC purities for all synthetic peptides 
Histone tail peptides MS [M+H]+ Purity 
ARTK(Me)QTARK(Me)STG  1332.8 (calcd. 1332.8) 98% 
Ac-ARTK(Me)-MCA  688.4 (calcd. 688.4) 100% 
Ac-ARTK(Me)2-MCA  702.4 (calcd. 702.4) 100% 
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3-3 Results and discussion 
 
A convenient route has been developed for the synthesis of Fmoc-Lys(Me)n-OH to be 
used as building block for the preparation of methylated peptides. This route used 
malonate derivatives and di-halogenated alkane to produce key intermediates 
2-amino-n-bromo-alkanoic acids which could be converted elegantly to functional 
amino acids. The synthesis started with commercially available diethyl 
acetamidomalonate. 1,4-dibromobutane was coupled with diethyl acetamidomalonate in 
the presence of sodium ethoxide in absolute ethanol. After few steps we got 
acetyl-DL-2-amino-6-bromohexanoic acid ethyl ester then reacted with methyl amine to 
get Ac-Lys(Me, Boc)-OEt which was converted to Ac-DL-Lys(Me, Boc)-OH by the 
action of NaOH in ethanol. Aspergillus genus L-aminoacylase (TCI) was applied to 
resolve the racemic mixture. After reacted with Fmoc-Osu, the desired Fmoc-L-Lys(Me, 
Boc)-OH was got and purified by silica gel chromatography. By the same way, 
Fmoc-L-Lys(Me)2-OH has been got succeed - produced starting with diethyl 
(Boc-amino)malonate and using (Me)2NH.HCl as methylating agent 
 
Two peptide-MCAs corresponding to the H3 (1-4) sequence were synthesized. Upon the 
action of trypsin and lysyl endopeptidase, neither Ac-ARTK(Me)-MCA nor 
Ac-ARTK(Me)2-MCA was hydrolyzed. This fact suggests the drastic change in 
susceptibility by methylation toward these enzymes. 
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In summary, the convenient and economical routes have been developed for the 
synthesis of Fmoc-L-Lys(Me, Boc)-OH and Fmoc-L-Lys(Me)2-OH to be used as 
building blocks for the synthesis of methylated peptides. N-Methyllysine residues have 
been efficiently incorporated to the H3 (1-12) peptide by automated solid phase peptide 
synthesis. Fmoc-L-Lys(Me, Boc)-OH and Fmoc-L-Lys(Me)2-OH are condensed with 
7-amino-4-methylcoumarin to prepare fluorescent peptide-MCAs, which are used to 
examine the susceptibilities to trypsin and lysyl endopeptidase. They showed no activity 
to mono- and dimethylated lysine peptides. 
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Fig. 1. Lysine methylation. (HMTs: Histone methyltransferases; LSDs: Lysine-specific 
demethylases). 
Chapter 4 
 
Fluorescent substrates of histone methyltransferases (HMTs) 
 
4-1 Introduction 
 
It had been introduced in the chapter 2 that the modification of histone N-terminal tails 
could affect the basic cellular functions such as DNA replication, transcription, 
differentiation and apoptosis. [1-9] Histone lysine methylation plays an important 
epigenetic role in the organization of chromation domains and the regulation of gene 
expression. [10-15] Lysines can be mono-, di-, or tri-methylated. (Fig. 1)  
 
It had been understood that the methylation of histone is induced by histone 
methyltransferases (HMTs). For many studies, the histone methylation is known to 
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associated with many diseases, such as HMTs SUV39H1 (shown overexpression in 
transgenic mice impairs differentiation), EZH2 (upregulated in tumour cell lines), MLL 
(translocated in leukaemias), NSD1 (can enhance androgen receptor Transactivation in 
prostate cancer), and RIZ (missense mutations in human tumour tissues and cell lines) 
are responsible for tumor development. [16-28] Also, the methylation of histone H3K9 
and H3K27 is observed together with increased DNA methylation and decreased histone 
acetylation in the promoter region of a cancer suppressor gene which expression is 
suppressed in cancer cells. [29-31] It also reported that increase methylation of histone 
H4K20 is found in common to many cancers. [32-34] The neurodegenerative diseases 
like myotonic dystrophy and Friedreich motor ataxia are also connected with the 
formation of a heterochromatin induced by the methylation of histone. [35] In  
addition, it is confirmed that iPS cells were induced by adding BayK8644 as an agonist 
of L-type calcium channels and BIX-01294 as an inhibitor for the HMTs G9a to 
Oct/Klf2 and gene-introduced mouse embryo fibroblasts. [36] (Table 1) 
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It is believed that HMTs inhibitor is expected as a therapeutic agent for diseases such as 
cancer and neurodegenerative disease and to be applied to regenerative medicine using 
iPS cells. Because the expectation and important of HTMs, some screening for these 
enzymes are developed. It is reported that one method called RI-method which involves 
mixing (methyl-3H)-SAM as S-adenosylmethionine (S-(5’-adenosyl)-L-methionine: 
SAM) (Fig. 2) whose methyl group is labeled with tritium, a peptide consisting an 
amino acid sequence of amino acid 1-19 of histone H3 (histone H3 (1-19) peptide), and 
a HMT for reaction, followed by measuring the radioactivity of the histone H3 (1-19) 
peptide to measure the amount of the methyl group transferred to lysine to thereby 
measure the histone methylation activity of the HMTs. [37] Also Elisa method is used 
for measuring HMTs inhibitors. (Fig. 3) [38] 
Table 1. The HMTS and the role of methylated histone lysine residue. 
Lysine site Transcriptional effect HMTs 
Histone H3K4 Transcription inhibition SET 1, MLL, SET7/9, 
SMYD3, Meisetz 
Histone H3K9 Transcription inhibition SUV39H1, G9a, GLP, 
ESET/SETDB1, RIZ 
Histone H3K27 Transcription inhibition MES-2, EZH2, G9a 
Histone H3K36 Transcription activation NSD1, SMYD2 
Histone H3K79 Transcription activation DOT1L 
Histone H4K20 Transcription inhibition SUV4-20H, NSD1, 
SET8/PR-SET7 
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Fig. 3. The Elisa method is used as conventional discovery of HMTs inhibiters (figure 
provided by RIKEN). 
 
 
Fig. 2. The RI-method which methyl marked by tritium were transferred to lysine. To 
measure the radioactivity, the activity of HMTs could be understood. SAM: 
S-(5’-adenosyl)-L-methionine; SAH: S-adenosyl-L-homocysteine.  
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In the above methods, some problems affect the developing of measuring way. It has 
been consider not so safe to use radioisotope, the complicated experimental procedures 
such as adsorption of a reaction product to filter paper and washing of the filter paper 
again and again. Also the Elisa method faces the experimental procedures problems and 
it takes plenty of times. As the developing studies of histone methylation, it requires 
measuring systems safe, sensitive and simply.  
 
4-2 Target 
 
To solve the problems mentioned in the last part of this chapter’s introduction, we hope 
to provide one method for detecting the HMTs activity and the inhibit activity of HMTs, 
we intend to develop one kit for those activities in the help of fluorescent substrate. 
 
4-3 Design 
 
We hope to establish one evaluation system that the methylation of the amino group of 
the lysine residue increases the intensity of detection of the dye simply and sensitive. 
The general step was shown in the Fig. 4. 
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We design the sequence of peptide-MCA as an abbreviation expressed as R-XK-D (R 
represent a hydrogen atom or a protecting group for an amino terminus; X represents a 
peptide consisting of zero or one or more amino acid residues; K represents a lysine 
residue; D represents one dye label linked via an amide bond to the carbonyl terminus 
of a lysine residue), wherein the cleavage of the amide bond by peptidase such as lysyl 
endopeptidase, endoproteinase Lys-C, plasmin, calpain, and trypsin, changes the 
fluorescence property or chromogenic property of the dye label and the methylation of 
the amino group of the lysine residue by the histone methyltransferase decreases 
susceptibility to peptidase; contacting the substrate compound represented by the 
general form R-XK-D or a salt thereof with a sample under conditions required for 
methylation reaction by the histone methyltransferase; exposing the substrate compound 
or a salt thereof to peptidase then measure the degree of the change of the fluorescence 
property or chromogenic property of the dye label to calculate the degree of the increase 
Peptide-Lys-MCA
Peptide-Lys(Me)n-MCA                 
Histone methyltransferases
(HMTs)
Peptide + AMC                 
trypsin
Peptide-Lys-MCA                 
trypsin
No reaction
 
Fig. 4. The principle of activity measurement.  
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of the methylation level of the substrate compound or a salt thereof, based on the 
peptidase that uses the substrate compound or a salt thereof as substrate; the degree of 
the increase of methylation level as the degree of HMTs activity in the sample.   
 
In the former described of general expressed for the substrate compound R-XK-D, R 
could be anything that is a hydrogen atom or a protecting group for an amino terminus, 
and specific examples of the amino-terminus protecting group can include –HCO, 
-CH3CO, -CH3CH2CO, a Boc (t-butyloxycarbonyl) group, a benzyl group, a propionyl 
group, and a tosyl group.  
 
D should be one dye label linked via an amide bond to the carbonyl terminus of the K 
(lysine residue) an whose fluorescence property is changed by the cleavage of the amide 
bond can be selected as 4-methyl-coumaryl-7-amide (MCA), 7-amino-4-chloromethyl- 
coumarin (CMCA), 2-aminonaphthalene-6-sulfonic acid (ANS), 7-amino-4-trifluoro- 
methylcoumarin (FMCA), and 2-amino-7-methylpurine-6-thiol (AMP). Because the 
pNA group and AN group which are described in the first chapter had secondary 
reaction, they are not considered. It should be has the ability for the specifically detected 
and quantified at the excitation wavelength and fluorescence wavelength before and 
after the cleavage clearly. According to the analyze the absorption wavelengths, 
excitation wavelength and fluorescence wavelength, in the substrate compound with 
MCA group, a wavelength exciting AMC without exciting MCA group (for example, 
360 nm to 400 nm, preferably 385 nm to 395 nm, particularly preferably 390 nm) is 
preferably irradiated to detect and measure a fluorescence wavelength (for example, 400 
nm to 500 nm, preferably 440 nm to 480 nm, particularly preferably 460 nm) emitted by 
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AMC for the specific measurement of AMC, and a wavelength exciting the MCA group 
(for example, 260 nm to 350 nm, preferably 300 nm to 340 nm, particularly preferably 
330 nm) is preferably irradiated to detect and measure a wavelength (for example, 350 
nm to 385 nm, preferably 365 nm to 385 nm, particularly preferably 380 nm) emitted 
not by AMC but by the MCA group for the specific measurement of the MCA group. 
The use of these wavelengths enables the simple and sensitive measurement of HMTs 
activity. 
 
In the general substrate compound R-XK-D, XK is a peptide derived from histone H4, 
p53, estrogen receptor (ER), androgen receptor (AR), glucocorticoid receptor (GE).  
Preferred examples of the XK derived from histone H3 can include a peptide consisting 
of the amino acid residues of amino acid 1-4 of human histone H3: ARTK; a peptide 
consisting of the amino acid residues of amino acid 5-9 of human histone H3: QTARK; 
a peptide consisting of the amino acid residues of amino acid 1-9 of human histone H3: 
ARTKQTARK; a peptide consisting of the amino acid residues of amino acid 7-9 or 
25-27 of human histone H3: ARK; a peptide consisting of the amino acid residues of 
amino acid 23-27 of human histone H3: KAARK; a peptide consisting of the amino 
acid residues of amino acid 19-27 of human histone H3: QLATKAARK. Preferred 
examples of the XK derived from p53 can include a peptide consisting of the amino 
acid residues of amino acid 369-372 of human p53: LKSK; a peptide consisting of the 
amino acid residues of amino acid 367-372 of human p53: SHLKSK. Preferred 
examples of the XK derived from ER can include a peptide consisting of the amino 
acid residues of amino acid 299-302 of human ERKRSK; a peptide consisting of the 
amino acid residues of amino acid 297-302 of human ERMIKRSK. Preferred 
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examples of the XK derived from AR can include a peptide consisting of the amino acid 
residues of amino acid 630-633 of human ARRKLK; a peptide consisting of the amino 
acid residues of amino acid 628-633 of human ARGARKLK. Preferred examples of 
the XK derived from GR can include a peptide consisting of the amino acid residues of 
amino acid 491-494 of human GRRKTK; a peptide consisting of the amino acid 
residues of amino acid 489-494 of human GREARKTK. (Table 2) 
Table 2. Ac-peptide-MCA as substrate of HMTs. ER: estrogen receptor ; AR: 
androgen receptor; GR: glucocorticoid receptor. 
Peptide-MCA Amino acid sequence 
Boc-Lys-MCA Boc-K-MCA 
Ac-histone H3 (1-4)-MCA Ac-ARTK-MCA 
Ac-histone H3 (5-9)-MCA Ac-QTARK-MCA 
Ac-histone H3 (1-9)-MCA Ac-ARTKQTARK-MCA 
Ac-histone H3 (7-9 / 25-27)-MCA Ac-ARK-MCA 
Ac-histone H3 (23-27)-MCA Ac-KAARK-MCA 
Ac-histone H3 (19-27)-MCA Ac-QLATKAARK-MCA 
Ac-p53 (369-372)-MCA Ac-LKSK-MCA 
Ac-p53 (367-372)-MCA Ac-SHLKSK-MCA 
Ac-ER (299-302)-MCA Ac-KRSK-MCA 
Ac-ER (297-302)-MCA Ac-MIKRSK-MCA 
Ac-AR (630-633)-MCA Ac-RKLK-MCA 
Ac-AR (628-633)-MCA Ac-GARKLK-MCA 
Ac-GR (491-494)-MCA Ac-RKTK-MCA 
Ac-GR (489-494)-MCA Ac-EARKTK-MCA 
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4-4 Experimental  
 
4-4-1 Synthesis of peptide-MCA 
 
General 
 
Unless otherwise noted, all solvents and reagents were reagent grade obtained from 
WAKO, Japan. Flash chromatography was performed using silica gel 60 (230–400 mesh) 
eluting with solvents as indicated. All compounds were routinely checked by thin layer 
chromatography (TLC) and/or high performance liquid chromatography (HPLC). TLC 
was performed on aluminum-backed silica gel plates (Merck DC-Alufolien Kieselgel 60 
F254) with spots visualized by UV light or charring. Analytical HPLC was performed on 
a Hitachi instrument equipped with a chromolith performance RP-18e column (4.6 × 
100 mm, Merck). The mobile phases used were A: H2O with 0.1% TFA, B: CH3CN 
with 0.1% TFA using a solvent gradient of A-B over 15 min with a flow rate of 2 
mL/min, with detection at 220 nm. HR FAB-mass spectra were measured on a JEOL 
JMS-SX 102A instrument.  
 
Automated solid phase peptide synthesis (SPPS) were assembled on Barlos resin 
(substitution 0.7 mmol/g) by automated solid phase peptide synthesis synthesizer 
(Applied Biosystems 433A) using Fmoc/piperidine strategies in FastMoc Chemistry at 
0.25 mmol scale. HBTU and HOBt.H2O were using as activating agent. The peptides 
were cleaved from the resin in the solution SP.DCM which content TFE and AcOH, 
reacted 2 hours. The removal of side chain functional protecting groups was carried out 
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with TFA containing phenol (5%), thinanisole (5%), ethanedithiol (2.5%) and water 
(5%). The peptides were precipitated by dry ethyl ether. Crude peptides were purified 
by size exclusion chromatography performed on a borosilicate glass column filled with 
sephaex G-25 using 10% acetic acid in water as eluent. The purified peptide products 
were identified by LC/MS. 
 
Manual solid phase peptide synthesis were also used to assemble peptides on Barlos 
resin (substitution 0.6 mmol/g) by manual solid phase peptide synthesis using 
Fmoc/piperidine strategies. Entering amino acids were preactivated with HBTU, 
HOBt.H2O, and DIEA in DMF for 5 min, and couplings were run for 1-2 h. Coupling 
efficiencies were monitored by Kaiser analysis. The removal of chain functional 
protected groups, resin cleavage and purification of crude peptides followed the same 
procedure as automated synthesis. 
 
4-4-1-1 Synthesis of Ac-ARTK-MCA 
 
Synthesis of Fmoc-Lys(Boc)-MCA 
 
To a chilled solution or suspension of Fmoc-Lys(Boc)-OH (1.86 g, 4 mmol) in DCM 
(10 mL) was added DCC (0.42 g, 2 mmol). After 1 hr reaction in ice bath, AMC (0.36 g, 
2 mmol) was added to the reaction mixture. The suspension was stirred at room 
temperature overnight. The compound was extracted with AcOEt, washed with 10% 
critic acid, 4% NaHCO3 and brine, MgSO4. Filtration and evaporation of AcOEt gave 
solid compound (1.13 g, 1.8 mmol, yield 90%). 
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Fmoc-Thr(tBu)-Lys(Boc)-MCA  
 
Fmoc-Lys(Boc)-MCA (1.13 g, 1.8 mmol) was dissolved in 20% piperidine/DMF (5 mL) 
and kept for 30 min at room temperature. After evaporation of piperidine and DMF, the 
residue was extracted with AcOEt, washed with sat. Na2CO3, dried over with anhydrous 
Na2CO3. The solution was concentrated to yield H-Lys(Boc)-MCA (0.73 g, 1.8 mmol, 
yield 100%).  
 
Fmoc-Thr(tBu)-OH (119 mg, 0.3 mmol) and H-Lys(Boc)-MCA (121 mg, 0.3 mmol) 
were dissolved in 10 mL DMF. To this chilled solution, HOBt.H2O (50 mg, 0.33 mmol, 
1.1 eq.), HBTU (125 mg, 0.33 mmol, 1.1 eq.) and DIEA (0.06 mL, 0.33 mmol, 1.1 eq.) 
were added. To react over night, TLC checked reaction completed. The compound 
Fmoc-Thr(tBu)-Lys(Boc)-MCA was extracted with AcOEt, washed with 10% critic acid, 
4% NaHCO3 and brine, dried over MgSO4. Filtration and evaporation of AcOEt gave 
white solid compound (384 mg, 0.25 mmol, yield 87%). 
 
Fmoc-Arg(Pmc)-Thr(tBu)-Lys(Boc)-MCA  
 
Fmoc-Thr(tBu)-Lys(Boc)-MCA (196 g, 0.25 mmol) was dissolved in 20% piperidine 
/DMF (5 mL) and kept for 30 min at room temperature. After evaporation of piperidine 
and DMF, the residue was extracted with AcOEt, washed with sat. Na2CO3, dried over 
with anhydrous Na2CO3. The solution was concentrated to yield H-Thr(
tBu)- 
Lys(Boc)-MCA (140 g, 0.25 mmol, yield 100%). 
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Fmoc-Arg(Pmc)-OH (165 mg, 0.25 mmol) and H-Thr(tBu)-Lys(Boc)-MCA (140 mg, 
0.25 mmol) were dissolved in 10 mL DMF. To this chilled solution, HOBt.H2O (42 mg, 
0.28 mmol, 1.1 eq.), HBTU (106 mg, 0.28 mmol, 1.1 eq.) and DIEA (0.05 mL, 0.28 
mmol, 1.1 eq.) were added. To react over night, TLC checked reaction completed. The 
compound Fmoc-Arg(Pmc)-Thr(tBu)-Lys(Boc)-MCA was extracted with AcOEt, 
washed with 10% critic acid, 4% NaHCO3 and brine, dried over MgSO4. Filtration and 
evaporation of AcOEt gave white solid compound (238 mg, 0.2 mmol, yield 82%). 
 
Fmoc-Ala-Arg(Pmc)-Ser(tBu)-Lys(Boc)-MCA 
 
Fmoc-Arg(Pmc)-Thr(tBu)-Lys(Boc)-MCA (241 mg, 0.2 mmol) was dissolved in 20% 
piperidine /DMF (5 mL) and kept for 30 min at room temperature. After evaporation of 
piperidine and DMF, the residue was extracted with AcOEt, washed with sat. Na2CO3, 
dried over with anhydrous Na2CO3. The solution was concentrated to yield 
H-Arg(Pmc)-Thr(tBu)- Lys(Boc)-MCA (197 mg, 0.2 mmol, yield 100%). 
 
Fmoc-Ala-OH (62 mg, 0.2 mmol) and H-Arg(Pmc)-Thr(tBu)- Lys(Boc)-MCA (197 mg, 
0.2 mmol) were dissolved in 5 mL DMF. To this chilled solution, HOBt.H2O (33 mg, 
0.22 mmol, 1.1 eq.), HBTU (83 mg, 0.22 mmol, 1.1 eq.) and DIEA (0.04 mL, 0.22 
mmol, 1.1 eq.) were added. To react 1 hr, HPLC checked reaction completed. The 
compound Fmoc-Ala-Arg(Pmc)-Thr(tBu)-Lys(Boc)-MCA was extracted with AcOEt, 
washed with 10% critic acid, 4% NaHCO3 and brine, dried over MgSO4. The solution 
was concentrated and the residues were applied to a silica gel column using a mixture of 
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methanol/chloroform (1:49) to get the Fmoc-Ala-Arg(Pmc)-Thr(tBu)-Lys(Boc)-MCA 
(168 mg, 0.14 mmol, yield 70%). 
 
Ac-Ala-Arg(Pmc)-Thr(tBu)-Lys(Boc)-MCA  
 
Fmoc-Ala-Arg(Pmc)-Thr(tBu)-Lys(Boc)-MCA (84 mg, 0.07 mmol) was dissolved in 
20% piperidine /DMF (6 mL) and kept for 30 min at room temperature. After 
evaporation of piperidine and DMF, the residue was extracted with AcOEt, washed with 
sat. Na2CO3, dried over with anhydrous Na2CO3. The solution was concentrated to yield 
H-Ala-Arg(Pmc)-Thr(tBu)-Lys(Boc)-MCA (75 mg, 0.07 mmol, yield 100%). Dissolve 
this compound in 5 mL DMF using ice bath to cool down. Added NEt3 (0.08 mmol, 1.1 
eq.) and Ac2O (0.08 mmol, 1.1 eq.) to react overnight. The solution was concentrated 
and the residues were crystallized in AcOEt. It gave Ac-Ala-Arg 
(Pmc)-Thr(tBu)-Lys(Boc)-MCA (76 mg, 0.07 mmol, yield 100%). 
 
Ac-Ala-Arg-Thr-Lys-MCA (AcOH)2  
 
Ac-Ala-Arg(Pmc)-Thr(tBu)-Lys(Boc)-MCA (76 mg, 0.07 mmol) was dissolved in a 
mixture of phenol/EDT/thioanisole/TFA/ water as 5/2.5/1/81.5/5 and allowed to stand at 
room temperature. After 1 hr, concentrated the solution and EtOtBu (20 mL) was added 
to precipitate white material, which was collected by centrifugation and washed with 
same EtOtBu. The column chromatography was performed with G-25 25% AcOH. It 
gave 100% purity compound 42 mg, 0.062 mmol. HR/MS (FAB) m/z calcd for [M+H]+ 
C31H48N9O8: 674.3626; found: 674.3607. 
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4-4-2-2 Synthesis of Ac-QTARK-MCA 
 
Synthesis of Fmoc-Arg(Pmc)-Lys(Boc)-MCA  
 
Fmoc-Lys(Boc)-MCA (1.13 g, 1.8 mmol) was dissolved in 20% piperidine/DMF (10 
mL) and kept for 30 min at room temperature. After evaporation of piperidine and DMF, 
the residue was extracted with AcOEt, washed with sat. Na2CO3, dried over with 
anhydrous Na2CO3. The solution was concentrated to yield H-Lys(Boc)-MCA (0.73 g, 
1.8 mmol, yield 100%).  
 
Fmoc-Arg(Pmc)-OH (92 mg, 0.14 mmol) and H-Lys(Boc)-MCA (57 mg, 0.14 mmol) 
were dissolved in 10 mL DMF. To this chilled solution, HOBt.H2O (23 mg, 0.15 mmol, 
1.1 eq.), HBTU (57 mg, 0.15 mmol, 1.1 eq.) and DIEA (0.03mL, 0.15 mmol, 1.1 eq.) 
were added. To react over night, TLC checked reaction completed. The compound 
Fmoc-Arg(Pmc)-Lys(Boc)-MCA was extracted with AcOEt, washed with 10% critic 
acid, 4% NaHCO3 and brine, dried over MgSO4. Filtration and evaporation of AcOEt 
gave white solid compound (125 mg, 0.12 mmol, yield 87%). 
 
Fmoc-Ala-Arg(Pmc)-Lys(Boc)-MCA  
 
Fmoc-Arg(Pmc)-Lys(Boc)-MCA (125 mg, 0.12 mmol) was dissolved in 20% piperidine 
/DMF (10 mL) and kept for 30 min at room temperature. After evaporation of piperidine 
and DMF, the residue was extracted with AcOEt, washed with sat. Na2CO3, dried over 
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with anhydrous Na2CO3. The solution was concentrated to yield 
H-Arg(Pmc)-Lys(Boc)-MCA (100 mg, 0.12 mmol, yield 100%). 
 
Fmoc-Ala-OH (37 mg, 0.12 mmol) and H-Arg(Pmc)-Lys(Boc)-MCA (100 mg, 0.12 
mmol) were dissolved in 10 mL DMF. To this chilled solution, HOBt.H2O (20 mg, 0.13 
mmol, 1.1 eq.), HBTU (45 mg, 0.13 mmol, 1.1 eq.) and DIEA (0.02 mL, 0.13 mmol, 1.1 
eq.) were added. To react 1 hour, TLC checked reaction completed. The compound 
Fmoc-Ala-Arg(Pmc)-Lys(Boc)-MCA was extracted with AcOEt, washed with 10% 
critic acid, 4% NaHCO3 and brine, dried over MgSO4. Filtration and evaporation of 
AcOEt gave white solid compound (114 mg, 0.09 mmol, yield 75%). 
 
Fmoc-Thr(tBu)-Ala-Arg(Pmc)-Lys(Boc)-MCA 
 
Fmoc-Ala-Arg(Pmc)-Lys(Boc)-MCA (114 mg, 0.09 mmol) was dissolved in 20% 
piperidine /DMF (10 mL) and kept for 30 min at room temperature. After evaporation of 
piperidine and DMF, the residue was extracted with AcOEt, washed with sat. Na2CO3, 
dried over with anhydrous Na2CO3. The solution was concentrated to yield 
H-Ala-Arg(Pmc)-Lys(Boc)-MCA (94 g, 0.09 mmol, yield 100%). 
 
Fmoc-Thr(tBu)-OH (34 mg, 0.09 mmol) and H-Ala-Arg(Pmc)-Lys(Boc)-MCA (94 mg, 
0.09 mmol) were dissolved in 7 mL DMF. To this chilled solution, HOBt.H2O (15 mg, 
0.1 mmol, 1.1 eq.), HBTU (38 mg, 0.1 mmol, 1.1 eq.) and DIEA (0.017 mL, 0.1 mmol, 
1.1 eq.) were added. To react 1 hr, HPLC checked reaction completed. The compound 
Fmoc-Thr(tBu)-Ala-Arg(Pmc)-Lys(Boc)-MCA was extracted with AcOEt, washed with 
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10% critic acid, 4% NaHCO3 and brine, dried over MgSO4. The solution was 
concentrated and the residues were applied to a silica gel column using a mixture of 
methanol/chloroform (1:49) to get the Fmoc-Thr(tBu)-Ala-Arg(Pmc)-Lys(Boc)-MCA 
(100 mg, 0.07 mmol, yield 88%). 
 
Fmoc-Gln(Trt)-Thr(tBu)-Ala-Arg(Pmc)-Lys(Boc)-MCA 
 
Fmoc-Thr(tBu)-Ala-Arg(Pmc)-Lys(Boc)-MCA (100 mg, 0.07 mmol) was dissolved in 
20% piperidine /DMF (10 mL) and kept for 30 min at room temperature. After 
evaporation of piperidine and DMF, the residue was extracted with AcOEt, washed with 
sat. Na2CO3, dried over with anhydrous Na2CO3. The solution was concentrated to yield 
H- Thr(tBu)-Ala-Arg(Pmc)-Lys(Boc)-MCA (84 mg, 0.07 mmol, yield 100%). 
 
Fmoc-Gln(Trt)-OH (41 mg, 0.07 mmol) and H-Thr(tBu)-Ala-Arg(Pmc)-Lys(Boc)-MCA 
(84 mg, 0.08 mmol) were dissolved in 7 mL DMF. To this chilled solution, HOBt.H2O 
(12 mg, 0.08 mmol, 1.1 eq.), HBTU (30 mg, 0.08 mmol, 1.1 eq.)and DIEA (0.014 mL, 
0.08 mmol, 1.1 eq.) were added. To react 1 hr, HPLC checked reaction completed. The 
compound Fmoc-Gln(Trt)-Thr(tBu)-Ala-Arg(Pmc)-Lys(Boc)-MCA was extracted with 
AcOEt, washed with 10% critic acid, 4% NaHCO3 and brine, dried over MgSO4. The 
solution was concentrated and the residues were applied to a silica gel column using a 
mixture of methanol/chloroform (1:49) to get the Fmoc-Gln(Trt)-Thr(tBu)-Ala- 
Arg(Pmc)-Lys(Boc)-MCA (88 mg, 0.05 mmol, yield 78%). 
 
Ac-Gln(Trt)-Thr(tBu)-Ala-Arg(Pmc)-Lys(Boc)-MCA  
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Fmoc-Gln(Trt)-Thr(tBu)-Ala-Arg(Pmc)-Lys(Boc)-MCA (88 mg, 0.05 mmol) was 
dissolved in 20% piperidine /DMF (6 mL) and kept for 30 min at room temperature. 
After evaporation of piperidine and DMF, the residue was extracted with AcOEt, 
washed with sat. Na2CO3, dried over with anhydrous Na2CO3. The solution was 
concentrated to yield H-Gln(Trt)-Thr(tBu)-Ala-Arg(Pmc)-Lys(Boc)-MCA (76 mg, 0.05 
mmol, yield 100%). Dissolve this compound in 5 mL DMF using ice bath to cool down. 
Added NEt3 (0.9 mmol, 1.1 eq.) and Ac2O (0.9 mmol, 1.1 eq.) to react overnight. The 
solution was concentrated and the residues were crystallized in AcOEt. It gave 
Ac-Gln(Trt)-Thr(tBu)-Ala-Arg(Pmc)-Lys(Boc)-MCA (78 mg, 0.05 mmol, yield 100%). 
 
Ac-Gln-Thr-Ala-Arg-Lys-MCA (AcOH)2  
 
Ac-Gln(Trt)-Thr(tBu)-Ala-Arg(Pmc)-Lys(Boc)-MCA (78 mg, 0.05 mmol) was 
dissolved in a mixture of phenol/EDT/thioanisole/TFA/ water as 5/2.5/1/81.5/5 and 
allowed to stand at room temperature. After 1 hr, concentrated the solution and EtOtBu 
(20 mL) was added to precipitate white material, which was collected by centrifugation 
and washed with same EtOtBu. The column chromatography was performed with G-25 
25% AcOH. It gave 100% purity compound 26 mg, 0.03 mmol. HR/MS (FAB) m/z 
calcd for [M+H]+ C36H56N11O10: 802.4212; found: 802.4192. 
 
4-4-2-3 Synthesis of Ac-ARTKQTARK-MCA 
 
Synthesis of Fmoc-Ala-Arg(Pmc)-Thr(tBu)-Lys(Boc)-Gln(Trt)-Thr(tBu)-Ala-Arg 
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(Pmc)-Barlos resin 
 
This peptide was assembled on Barlos resin (substitution 0.7 mmol/g) by automated 
solid phase peptide synthesis synthesizer as we describe in the general part (FastMoc 
Chemistry at 0.25 mmol scale).  
 
Ac-AR(Pmc)T(tBu)K(Boc)Q(Trt)T(tBu)AR(Pmc)-OH  
 
The N-terminal protecting group was removed in the addition of 20% piperidine/DMF 
(5 mL) and kept for 30 min at room temperature. The acetylation was carried out in the 
solvent of DMF (5 mL) at the addition of NEt3 (0.25 mmol, 1 eq.) and Ac2O (0.25 mmol, 
1 eq.) to react 2 hours. The cleavage was processed following general part description. 
 
Ac-AR(Pmc)T(tBu)K(Boc)Q(Trt)T(tBu)AR(Pmc)K(Boc)-MCA 
 
Fmoc-Lys(Boc)-MCA (1.13 g, 1.8 mmol) was dissolved in 20% piperidine/DMF (10 
mL) and kept for 30 min at room temperature. After evaporation of piperidine and DMF, 
the residue was extracted with AcOEt, washed with sat. Na2CO3, dried over with 
anhydrous Na2CO3. The solution was concentrated to yield H-Lys(Boc)-MCA (0.73 g, 
1.8 mmol, yield 100%). 
 
Ac-Ala-Arg(Pmc)-Thr(tBu)-Lys(Boc)-Qln(Trt)-Thr(tBu)-Ala-Arg(Pmc)-OH (428 mg, 
0.22 mmol) and H-Lys(Boc)-MCA (0.73 g, 0.22 mmol) were dissolved in 10 mL DMF. 
To this chilled solution, HOBt.H2O (36 mg, 0.24 mmol, 1.1 eq.), HBTU (90 mg, 0.24 
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mmol, 1.1 eq.) and DIEA (0.04 mL, 0.24 mmol, 1.1 eq.) were added. To react over 2 
hours, TLC checked reaction completed. This compound was extracted with AcOEt, 
washed with 10% critic acid, 4% NaHCO3 and brine, dried over MgSO4. Filtration and 
evaporation of AcOEt gave desired compound (470 mg, 0.2 mmol, yield 90%). 
 
Ac-Ala-Arg-Thr-Lys-Gln-Thr-Ala-Arg-Lys-MCA (AcOH)4 
 
The removal side chain functional protecting groups of Ac-Ala-Arg(Pmc)-Thr(tBu) 
-Lys(Boc)-Qln(Trt)-Thr(tBu)-Ala-Arg(Pmc)-Lys(Boc)-MCA (470 mg, 0.2 mmol) was 
carried out in the addition of TFA containing phenol (5%), thinanisole (5%), 
ethanedithiol (2.5%) and water (5%). The peptides were precipitated by dry ethyl ether. 
Crude peptides were purified by size exclusion chromatography performed on a 
borosilicate glass column filled with sephaex G-25 using 10% acetic acid in water as 
eluent. It gave 100% purity compound 20 mg, 0.016 mmol. HR/MS (FAB) m/z calcd for 
[M+H]+ C55H92N19O15: 1258.7020; found: 1258.6858. 
 
4-4-2-4 Synthesis of Ac-ARK-MCA 
 
Synthesis of Fmoc-Arg(Pmc)-Lys(Boc)-MCA  
 
Fmoc-Lys(Boc)-MCA (620 mg, 1 mmol) was dissolved in 20% piperidine/DMF (5 mL) 
and kept for 30 min at room temperature. After evaporation of piperidine and DMF, the 
residue was extracted with AcOEt, washed with sat. Na2CO3, dried over with anhydrous 
Na2CO3. The solution was concentrated to yield H-Lys(Boc)-MCA (404 mg, 1 mmol, 
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yield 100%).  
 
Fmoc-Arg(Pmc)-OH (73 g, 0.11 mmol) and H-Lys(Boc)-MCA (45 mg, 0.11 mmol) 
were dissolved in 10 mL DMF. To this chilled solution, HOBt.H2O (18 mg, 0.12 mmol, 
1.1 eq.), HBTU (45 mg, 2 mmol, 1.1 eq.) and DIEA (0.02mL, 2 mmol, 1.1 eq.) were 
added. To react over night, TLC checked reaction completed. The compound Fmoc- 
Arg(Pmc)-Lys(Boc)-MCA was extracted with AcOEt, washed with 10% critic acid, 4% 
NaHCO3 and brine, dried over MgSO4. Filtration and evaporation of AcOEt gave white 
solid compound (104 mg, 0.1 mmol, yield 89%). 
 
Fmoc-Ala-Arg(Pmc)-Lys(Boc)-MCA  
 
Fmoc-Arg(Pmc)-Lys(Boc)-MCA (104 mg, 0.1 mmol) was dissolved in 20% piperidine 
/DMF (10 mL) and kept for 30 min at room temperature. After evaporation of piperidine 
and DMF, the residue was extracted with AcOEt, washed with sat. Na2CO3, dried over 
with anhydrous Na2CO3. The solution was concentrated to yield H-Arg(Pmc)- 
Lys(Boc)-MCA (82 mg, 0.1 mmol, yield 100%). 
 
Fmoc-Ala-OH (31 mg, 0.1 mmol) and H-Arg(Pmc)-Lys(Boc)-MCA (82 mg, 0.1 mmol) 
were dissolved in 10 mL DMF. To this chilled solution, HOBt.H2O (17 mg, 0.11 mmol, 
1.1 eq.), HBTU (38 mg, 0.11 mmol, 1.1 eq.) and DIEA (0.02 mL, 0.11 mmol, 1.1 eq.) 
were added. To react over night, TLC checked reaction completed. The compound 
Fmoc-Ala-Arg(Pmc)-Lys(Boc)-MCA was extracted with AcOEt, washed with 10% 
critic acid, 4% NaHCO3 and brine, dried over MgSO4. Filtration and evaporation of 
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AcOEt gave white solid compound (84 mg, 0.08 mmol, yield 82%). 
 
Ac-Ala-Arg(Pmc)-Lys(Boc)-MCA  
 
Fmoc-Ala-Arg(Pmc)-Lys(Boc)-MCA (84 mg, 0.08 mmol) was dissolved in 20% 
piperidine /DMF (6 mL) and kept for 30 min at room temperature. After evaporation of 
piperidine and DMF, the residue was extracted with AcOEt, washed with sat. Na2CO3, 
dried over with anhydrous Na2CO3. The solution was concentrated to yield 
H-Ala-Arg(Pmc)-Lys(Boc)-MCA (66 mg, 0.08 mmol, yield 100%). Dissolve this 
compound in 5 mL DMF using ice bath to cool down. Added NEt3 (0.9 mmol, 1.1 eq.) 
and Ac2O (0.9 mmol, 1.1 eq.) to react overnight. The solution was concentrated and the 
residues were crystallized in AcOEt. It gave Ac-Ala-Arg (Pmc)-Lys(Boc)-MCA (75 mg, 
0.08 mmol, yield 100%). 
 
Ac-Ala-Arg-Lys-MCA (AcOH)2  
 
Ac-Ala-Arg(Pmc)-Lys(Boc)-MCA (75 mg, 0.08 mmol) was dissolved in a mixture of 
phenol/EDT/thioanisole/TFA/ water as 5/2.5/1/81.5/5 and allowed to stand at room 
temperature. After 1 hr, concentrated the solution and EtOtBu (20 mL) was added to 
precipitate white material, which was collected by centrifugation and washed with same 
EtOtBu. The column chromatography was performed with G-25 25% AcOH. It gave 
100% purity compound 32 mg, 0.06 mmol. HR/MS (FAB) m/z calcd for [M+H]+ 
C27H41N8O6: 573.3149; found: 573.3113. 
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4-4-2-5 Synthesis of Ac-KAARK-MCA 
 
Synthesis of Fmoc-Lys(Boc)-Ala-Ala-Arg(Pmc)-Lys(Boc)-Barlos resin 
 
This peptide was assembled on Barlos resin (substitution 0.7 mmol/g) by manual solid 
phase peptide synthesis as we described in the general part (0.25 mmol scale). 
 
Ac-Lys(Boc)-Ala-Ala-Arg(Pmc)-Lys(Boc)-OH 
 
The N-terminal protecting group was removed in the addition of 20% piperidine/DMF 
(5 mL) and kept for 30 min at room temperature. The acetylation was carried out in the 
solvent of DMF (5 mL) at the addition of NEt3 (0.25 mmol, 1 eq.) and Ac2O (0.25 mmol, 
1 eq.) to react 2 hours. The cleavage was processed following general part description. 
 
Ac-Lys(Boc)-Ala-Ala-Arg(Pmc)-Lys(Boc)-MCA  
 
Fmoc-Lys(Boc)-MCA (662 mg, 1 mmol) was dissolved in 20% piperidine/DMF (10 
mL) and kept for 30 min at room temperature. After evaporation of piperidine and DMF, 
the residue was extracted with AcOEt, washed with sat. Na2CO3, dried over with 
anhydrous Na2CO3. The solution was concentrated to yield H-Lys(Boc)-MCA (404 mg, 
1 mmol, yield 100%). 
 
Ac-Lys(Boc)-Ala-Ala-Arg(Pmc)-OH (192 mg, 0.23 mmol) and H-Lys(Boc)-MCA (92 
mg, 0.23 mmol) were dissolved in 5 mL DMF. To this chilled solution, HOBt.H2O (36 
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mg, 0.24 mmol, 1.1 eq.), HBTU (90 mg, 0.24 mmol, 1.1 eq.) and DIEA (0.04 mL, 0.24 
mmol, 1.1 eq.) were added. To react over 2 hours, TLC checked reaction completed. 
This compound was extracted with AcOEt, washed with 10% critic acid, 4% NaHCO3 
and brine, dried over MgSO4. Filtration and evaporation of AcOEt gave desired 
compound (193 mg, 0.15 mmol, yield 68%). 
 
Ac-Lys-Ala-Ala-Arg-Lys-MCA (AcOH)3  
 
Ac-Ala-Arg(Pmc)-Thr(tBu)-Lys(Boc)-MCA (60 mg, 0.05 mmol) was dissolved in a 
mixture of phenol/EDT/thioanisole/TFA/ water as 5/2.5/1/81.5/5 and allowed to stand at 
room temperature. After 1 hr, concentrated the solution and EtOtBu (20 mL) was added 
to precipitate white material, which was collected by centrifugation and washed with 
same EtOtBu. The column chromatography was performed with G-25 25% AcOH. It 
gave 93% purity compound 15 mg, 0.02 mmol. HR/MS (FAB) m/z calcd for [M+H]+ 
C36H58N11O8: 772.7740; found: 772.4436. 
 
4-4-2-6 Synthesis of Ac-QLATKAARK-MCA 
 
Synthesis of Fmoc-Gln(Trt)-Leu-Ala-Thr(tBu)-Lys(Boc)-Ala-Ala-Arg(Pmc)-Barlos  
resin 
 
This peptide was assembled on Barlos resin (substitution 0.7 mmol/g) by automated 
solid phase peptide synthesis synthesizer as we describe in the general part (FastMoc 
Chemistry at 0.25 mmol scale).  
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Ac-Gln(Trt)-Leu-Ala-Thr(tBu)-Lys(Boc)-Ala-Ala-Arg(Pmc)-OH  
 
The N-terminal protecting group was removed in the addition of 20% piperidine/DMF 
(5 mL) and kept for 30 min at room temperature. The acetylation was carried out in the 
solvent of DMF (5 mL) at the addition of NEt3 (0.25 mmol, 1 eq.) and Ac2O (0.25 mmol, 
1eq.) to react 2 hours. The cleavage was processed following general part description. 
 
Ac-Gln(Trt)-Leu-Ala-Thr(tBu)-Lys(Boc)-Ala-Ala-Arg(Pmc)-Lys(Boc)-MCA 
 
Fmoc-Lys(Boc)-MCA (660 g, 1 mmol) was dissolved in 20% piperidine/DMF (5 mL) 
and kept for 30 min at room temperature. After evaporation of piperidine and DMF, the 
residue was extracted with AcOEt, washed with sat. Na2CO3, dried over with anhydrous 
Na2CO3. The solution was concentrated to yield H-Lys(Boc)-MCA (404 g, 1 mmol, 
yield 100%). 
 
Ac-Gln(Trt)-Leu-Ala-Thr(tBu)-Lys(Boc)-Ala-Ala-Arg(Pmc)-OH (154 mg, 0.1 mmol) 
and H-Lys(Boc)-MCA (40 g, 0.1 mmol) were dissolved in 2 mL DMF. To this chilled 
solution, HOBt.H2O (17 mg, 0.11 mmol, 1.1 eq.), HBTU (42 mg, 0.11 mmol, 1.1 eq.) 
and DIEA (0.02 mL, 0.11 mmol, 1.1 eq.) were added. To react over 2 hours, TLC 
checked reaction completed. This compound was extracted with AcOEt, washed with 
10% critic acid, 4% NaHCO3 and brine, dried over MgSO4. Filtration and evaporation 
of AcOEt gave desired compound (136 mg, 0.07 mmol, yield 73%). 
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Ac-Gln-Leu-Ala-Thr-Lys-Ala-Ala-Arg-Lys-MCA. AcOH 
 
The removal side chain functional protecting groups of Ac-Gln(Trt)-Leu-Ala-Thr(tBu)- 
Lys(Boc)-Ala-Ala-Arg(Pmc)-Lys(Boc)-MCA (136 mg, 0.07 mmol) was carried out in 
the addition of TFA containing phenol (5%), thinanisole (5%), ethanedithiol (2.5%) and 
water (5%). The peptides were precipitated by dry ethyl ether. Crude peptides were 
purified by size exclusion chromatography performed on a borosilicate glass column 
filled with sephaex G-25 using 10% acetic acid in water as eluent. The purified peptide 
products were identified by LC/MS. It gave 100% purity compound 28 mg, 0.024 mmol. 
HR/MS (FAB) m/z calcd for [M+H]+ C54H89N16O14: 1185.6744; found: 1185.6716. 
 
4-4-2-7 Synthesis of Ac-LKSK-MCA 
 
Synthesis of Fmoc-Leu-Lys(Boc)-Ser(tBu)-Barlos resion  
 
This peptide was assembled on Barlos resin (substitution 0.7 mmol/g) by manual solid 
phase peptide synthesis as we described in the general part (0.25 mmol scale). 
 
Ac-Leu-Lys(Boc)-Ser(tBu)-OH 
 
The N-terminal protecting group was removed in the addition of 20% piperidine/DMF 
(5 mL) and kept for 30 min at room temperature. The acetylation was carried out in the 
solvent of DMF (5 mL) at the addition of NEt3 (0.25 mmol, 1 eq.) and Ac2O (0.25 mmol, 
1 eq.) to react 2 hours. The cleavage was processed following general part description. 
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Ac-Leu-Lys(Boc)-Ser(tBu)-Lys(Boc)-MCA  
 
Fmoc-Lys(Boc)-MCA (662 mg, 1 mmol) was dissolved in 20% piperidine/DMF (10 
mL) and kept for 30 min at room temperature. After evaporation of piperidine and DMF, 
the residue was extracted with AcOEt, washed with sat. Na2CO3, dried over with 
anhydrous Na2CO3. The solution was concentrated to yield H-Lys(Boc)-MCA (404 mg, 
1 mmol, yield 100%). 
 
Ac-Leu-Lys(Boc)-Ser(tBu)-OH (115 mg, 0.22 mmol) and H-Lys(Boc)-MCA (89 mg, 
0.22 mmol) were dissolved in 5 mL DMF. To this chilled solution, HOBt.H2O (36 mg, 
0.24 mmol, 1.1 eq.), HBTU (90 mg, 0.24 mmol, 1.1 eq.) and DIEA (0.04 mL, 0.24 
mmol, 1.1 eq.) were added. To react over 2 hours, TLC checked reaction completed. 
This compound was extracted with AcOEt, washed with 10% critic acid, 4% NaHCO3 
and brine, dried over MgSO4. Filtration and evaporation of AcOEt gave desired 
compound (168 mg, 0.18 mmol, yield 81%). 
 
Ac-Leu-Lys-Ser-Lys-MCA (AcOH)2  
 
Ac-Leu-Lys(Boc)-Ser(tBu)-Lys(Boc)-MCA (168 mg, 0.18 mmol) was dissolved in a 
mixture of phenol/EDT/thioanisole/TFA/ water as 5/2.5/1/81.5/5 and allowed to stand at 
room temperature. After 1 hr, concentrated the solution and EtOtBu (20 mL) was added 
to precipitate white material, which was collected by centrifugation and washed with 
same EtOtBu. The column chromatography was performed with G-25 25% AcOH. It 
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gave 100% purity compound 25 mg, 0.04 mmol. HR/MS (FAB) m/z calcd for [M+H]+ 
C31H48N9O8: 674.3626; found: 674.3658. 
 
4-4-2-8 Synthesis of Ac-SHLKSK-MCA 
 
Synthesis of Fmoc-Ser(tBu)-His-Leu-Lys(Boc)-Ser(tBu)-Barlos resin 
 
This peptide was assembled on Barlos resin (substitution 0.7 mmol/g) by automated 
solid phase peptide synthesis synthesizer as we describe in the general part (FastMoc 
Chemistry at 0.25 mmol scale).  
 
Ac-Ser(tBu)-His-Leu-Lys(Boc)-Ser(tBu)-OH  
 
The N-terminal protecting group was removed in the addition of 20% piperidine/DMF 
(5 mL) and kept for 30 min at room temperature. The acetylation was carried out in the 
solvent of DMF (5 mL) at the addition of NEt3 (0.25 mmol, 1 eq.) and Ac2O (0.25 mmol, 
1 eq.) to react 2 hours. The cleavage was processed following general part description. 
 
Ac-Ser(tBu)-His-Leu-Lys(Boc)-Ser(tBu)-Lys(Boc)-MCA 
 
Fmoc-Lys(Boc)-MCA (660 mg, 1 mmol) was dissolved in 20% piperidine/DMF (5 mL) 
and kept for 30 min at room temperature. After evaporation of piperidine and DMF, the 
residue was extracted with AcOEt, washed with sat. Na2CO3, dried over with anhydrous 
Na2CO3. The solution was concentrated to yield H-Lys(Boc)-MCA (400 mg, 1 mmol, 
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yield 100%). 
 
Ac-Ser(tBu)-His-Leu-Lys(Boc)-Ser(tBu)-OH (120 mg, 0.15 mmol) and 
H-Lys(Boc)-MCA (60 mg, 0.15 mmol) were dissolved in 2 mL DMF. To this chilled 
solution, HOBt.H2O (24 mg, 0.16 mmol, 1.1 eq.), HBTU (60 mg, 0.16 mmol, 1.1 eq.) 
and DIEA (0.03 mL, 0.16 mmol, 1.1 eq.) were added. To react over 2 hours, TLC 
checked reaction completed. This compound was extracted with AcOEt, washed with 
10% critic acid, 4% NaHCO3 and brine, dried over MgSO4. Filtration and evaporation 
of AcOEt gave desired compound (120 mg, 0.1 mmol, yield 66%). 
 
Ac-Ser-His-Leu-Lys-Ser-Lys-MCA (AcOH)2 
 
The removal side chain functional protecting groups of Ac-Ser(tBu)-His-Leu-Lys(Boc)- 
Ser(tBu)-Lys(Boc)-MCA (120 mg, 0.1 mmol) was carried out in the addition of TFA 
containing phenol (5%), thinanisole (5%), ethanedithiol (2.5%) and water (5%). The 
peptides were precipitated by dry ethyl ether. Crude peptides were purified by size 
exclusion chromatography performed on a borosilicate glass column filled with sephaex 
G-25 using 10% acetic acid in water as eluent. The purified peptide products were 
identified by LC/MS. It gave 100% purity compound 32 mg, 0.03 mmol. HR/MS (FAB) 
m/z calcd for [M+H]+ C42H64N11O11: 898.4709; found: 898.4748. 
 
4-4-2-9 Synthesis of Ac-KRSK-MCA 
 
Synthesis of Fmoc-Ser(tBu)-Lys(Boc)-MCA  
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Fmoc-Lys(Boc)-MCA (1.13 g, 1.8 mmol) was dissolved in 20% piperidine/DMF (10 
mL) and kept for 30 min at room temperature. After evaporation of piperidine and DMF, 
the residue was extracted with AcOEt, washed with sat. Na2CO3, dried over with 
anhydrous Na2CO3. The solution was concentrated to yield H-Lys(Boc)-MCA (0.73 g, 
1.8 mmol, yield 100%).  
 
Fmoc-Ser(tBu)-OH (0.76 g, 2.0 mmol) and H-Lys(Boc)-MCA (0.73 g, 1.8 mmol) were 
dissolved in 10 mL DMF. To this chilled solution, HOBt.H2O (2 mmol, 1.1 eq.), HBTU 
(2 mmol, 1.1 eq.) and DIEA (2 mmol, 1.1 eq.) were added. To react over night, TLC 
checked reaction completed. The compound Fmoc-Ser(tBu)-Lys(Boc)-MCA was 
extracted with AcOEt, washed with 10% critic acid, 4% NaHCO3 and brine, dried over 
MgSO4. Filtration and evaporation of AcOEt gave white solid compound (1.2 g, 1.5 
mmol, yield 86%). 
 
Fmoc-Arg(Pmc)-Ser(tBu)-Lys(Boc)-MCA  
 
Fmoc-Ser(tBu)-Lys(Boc)-MCA (1.2 g, 1.5 mmol) was dissolved in 20% piperidine 
/DMF (10 mL) and kept for 30 min at room temperature. After evaporation of piperidine 
and DMF, the residue was extracted with AcOEt, washed with sat. Na2CO3, dried over 
with anhydrous Na2CO3. The solution was concentrated to yield H-Ser(
tBu)- 
Lys(Boc)-MCA (0.55 g, 1.5 mmol, yield 100%). 
Fmoc-Arg(Pmc)-OH (1.06 g, 1.6 mmol) and H-Ser(tBu)-Lys(Boc)-MCA (0.55 g, 1.5 
mmol) were dissolved in 10 mL DMF. To this chilled solution, HOBt.H2O (1.65 mmol, 
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1.1 eq.), HBTU (1.65 mmol, 1.1 eq.) and DIEA (1.65 mmol, 1.1 eq.) were added. To 
react over night, TLC checked reaction completed. The compound Fmoc-Arg 
(Pmc)-Ser(tBu)-Lys(Boc)-MCA was extracted with AcOEt, washed with 10% critic acid, 
4% NaHCO3 and brine, dried over MgSO4. Filtration and evaporation of AcOEt gave 
white solid compound (1.5 g, 1.26 mmol, yield 84%). 
 
Fmoc-Lys(Boc)-Arg(Pmc)-Ser(tBu)-Lys(Boc)-MCA 
 
Fmoc-Arg(Pmc)-Ser(tBu)-Lys(Boc)-MCA (1.5 g, 1.26 mmol) was dissolved in 20% 
piperidine /DMF (10 mL) and kept for 30 min at room temperature. After evaporation of 
piperidine and DMF, the residue was extracted with AcOEt, washed with sat. Na2CO3, 
dried over with anhydrous Na2CO3. The solution was concentrated to yield 
H-Arg(Pmc)-Ser(tBu)- Lys(Boc)-MCA (1.22 g, 1.26 mmol, yield 100%). 
 
Fmoc-Lys(Boc)-OH (0.65 g, 1.4 mmol) and H-Ser(tBu)-Lys(Boc)-MCA (1.22 g, 1.26 
mmol) were dissolved in 7 mL DMF. To this chilled solution, HATU (1.4 mmol, 1.1 eq.) 
and DIEA (1.4 mmol, 1.1 eq.) were added. To react 1 hr, HPLC checked reaction 
completed. The compound Fmoc-Lys(Boc)-Arg(Pmc)-Ser(tBu)-Lys(Boc)-MCA was 
extracted with AcOEt, washed with 10% critic acid, 4% NaHCO3 and brine, dried over 
MgSO4. The solution was concentrated and the residues were applied to a silica gel 
column using a mixture of methanol/chloroform (1:49) to get the Fmoc-Lys(Boc) 
-Arg(Pmc)-Ser(tBu)-Lys(Boc)-MCA (1.1 g, 0.8 mmol, yield 62%). 
 
Ac-Lys(Boc)-Arg(Pmc)-Ser(tBu)-Lys(Boc)-MCA  
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Fmoc-Lys(Boc)-Arg(Pmc)-Ser(tBu)-Lys(Boc)-MCA (1.1 g, 0.8 mmol) was dissolved in 
20% piperidine /DMF (6 mL) and kept for 30 min at room temperature. After 
evaporation of piperidine and DMF, the residue was extracted with AcOEt, washed with 
sat. Na2CO3, dried over with anhydrous Na2CO3. The solution was concentrated to yield 
H-Lys(Boc)-Arg(Pmc)-Ser(tBu)-Lys(Boc)-MCA (0.96 g, 0.8 mmol, yield 100%). 
Dissolve this compound in 5 mL DMF using ice bath to cool down. Added NEt3 (0.9 
mmol, 1.1 eq.) and Ac2O (0.9 mmol, 1.1 eq.) to react overnight. The solution was 
concentrated and the residues were crystallized in AcOEt. It gave Ac-Lys(Boc)-Arg 
(Pmc)-Ser(tBu)-Lys(Boc)-MCA (1.0 g, 0.8 mmol, yield 100%). 
 
Ac-Lys-Arg-Ser-Lys-MCA (AcOH)3  
 
Ac-Lys(Boc)-Arg(Pmc)-Ser(tBu)-Lys(Boc)-MCA (1.0 g, 0.8 mmol) was dissolved in a 
mixture of phenol/EDT/thioanisole/TFA/ water as 5/2.5/1/81.5/5 and allowed to stand at 
room temperature. After 1 hr, concentrated the solution and EtOtBu (20 mL) was added 
to precipitate white material, which was collected by centrifugation and washed with 
same EtOtBu. The column chromatography was performed with G-25 25% AcOH. It 
gave 100% purity compound 0.5 g, 0.55 mmol. HR/MS (FAB) m/z calcd for [M+H]+ 
C33H53N10O8: 717.3770; found: 717.4039. 
 
4-4-2-10 Synthesis of Ac-MIKRSK-MCA 
 
Synthesis of Fmoc-Met-Ile-Lys(Boc)-Arg(Pmc)-Ser(tBu)-Barlos resin 
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This peptide was assembled on Barlos resin (substitution 0.7 mmol/g) by automated 
solid phase peptide synthesis synthesizer as we describe in the general part (FastMoc 
Chemistry at 0.25 mmol scale).  
 
Ac-Met-Ile-Lys(Boc)-Arg(Pmc)-Ser(tBu)-OH  
 
The N-terminal protecting group was removed in the addition of 20% piperidine/DMF 
(5 mL) and kept for 30 min at room temperature. The acetylation was carried out in the 
solvent of DMF (5 mL) at the addition of NEt3 (0.25 mmol, 1 eq.) and Ac2O (0.25 mmol, 
1 eq.) to react 2 hours. The cleavage was processed following general part description. 
 
Ac-Met-Ile-Lys(Boc)-Arg(Pmc)-Ser(tBu)-Lys(Boc)-MCA 
 
Fmoc-Lys(Boc)-MCA (660 mg, 1 mmol) was dissolved in 20% piperidine/DMF (5 mL) 
and kept for 30 min at room temperature. After evaporation of piperidine and DMF, the 
residue was extracted with AcOEt, washed with sat. Na2CO3, dried over with anhydrous 
Na2CO3. The solution was concentrated to yield H-Lys(Boc)-MCA (404 mg, 1 mmol, 
yield 100%). 
 
Ac-Met-Ile-Lys(Boc)-Arg(Pmc)-Ser(tBu)-OH (107 mg, 0.11 mmol) and H-Lys(Boc)- 
MCA (44 mg, 0.11 mmol) were dissolved in 2 mL DMF. To this chilled solution, 
HOBt.H2O (18 mg, 0.12 mmol, 1.1 eq.), HBTU (45 mg, 0.12 mmol, 1.1 eq.) and DIEA 
(0.02 mL, 0.12 mmol, 1.1 eq.) were added. To react over 2 hours, TLC checked reaction 
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completed. This compound was extracted with AcOEt, washed with 10% critic acid, 4% 
NaHCO3 and brine, dried over MgSO4. Filtration and evaporation of AcOEt gave 
desired compound (97 mg, 0.07 mmol, yield 63%). 
 
Ac-Met-Ile-Lys-Arg-Ser-Lys-MCA (AcOH)3 
 
The removal side chain functional protecting groups of Ac-Met-Ile-Lys(Boc)-Arg(Pmc)- 
Ser(tBu)-Lys(Boc)-MCA (97 g, 0.07 mmol) was carried out in the addition of TFA 
containing phenol (5%), thinanisole (5%), ethanedithiol (2.5%) and water (5%). The 
peptides were precipitated by dry ethyl ether. Crude peptides were purified by size 
exclusion chromatography performed on a borosilicate glass column filled with sephaex 
G-25 using 10% acetic acid in water as eluent. It gave 100% purity compound 28 mg, 
0.03 mmol. HR/MS (FAB) m/z calcd for [M+H]+ C44H73N12O10: 961.5215; found: 
961.5269. 
 
4-4-2-11 Synthesis of Ac-RKLK-MCA 
 
Synthesis of Fmoc-Arg(Pmc)-Lys(Boc)-Leu-Barlos resion  
 
This peptide was assembled on Barlos resin (substitution 0.7 mmol/g) by manual solid 
phase peptide synthesis as we described in the general part (0.25 mmol scale). 
 
Ac-Arg(Pmc)-Lys(Boc)-Leu-OH 
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The N-terminal protecting group was removed in the addition of 20% piperidine/DMF 
(5 mL) and kept for 30 min at room temperature. The acetylation was carried out in the 
solvent of DMF (5 mL) at the addition of NEt3 (0.25 mmol, 1 eq.) and Ac2O (0.25 mmol, 
1 eq.) to react 2 hours. The cleavage was processed following general part description. 
 
Ac-Arg(Pmc)-Lys(Boc)-Leu-Lys(Boc)-MCA 
 
Ac-Arg(Pmc)-Lys(Boc)-Leu-OH (169 mg, 0.21 mmol) H-Lys(Boc)-MCA (84 mg, 0.21 
mmol) were dissolved in 2 mL DMF. To this chilled solution, HOBt.H2O (35 mg, 0.23 
mmol, 1.1 eq.), HBTU (87 mg, 0.23 mmol, 1.1 eq.) and DIEA (0.04 mL, 0.23 mmol, 1.1 
eq.) were added. To react over 2 hours, TLC checked reaction completed. This 
compound was extracted with AcOEt, washed with 10% critic acid, 4% NaHCO3 and 
brine, dried over MgSO4. Filtration and evaporation of AcOEt gave desired compound 
(193 mg, 0.16 mmol, yield 78%). 
 
Ac-Arg-Lys-Leu-Lys-MCA (AcOH)3  
 
Ac-Arg(Pmc)-Lys(Boc)-Leu-Lys(Boc)-MCA (80 mg, 0.06 mmol) was dissolved in a 
mixture of phenol/EDT/thioanisole/TFA/ water as 5/2.5/1/81.5/5 and allowed to stand at 
room temperature. After 1 hr, concentrated the solution and EtOtBu (20 mL) was added 
to precipitate white material, which was collected by centrifugation and washed with 
same EtOtBu. The column chromatography was performed with G-25 25% AcOH. It 
gave 100% purity compound 30 mg, 0.04 mmol. LC/MS m/z calcd for [M+H]+: 
743.4568; found: 743.5. 
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4-4-2-12 Synthesis of Ac-GARKLK-MCA 
 
Synthesis of Fmoc-Gly-Ala-Arg(Pmc)-Lys(Boc)-Leu-Barlos resin 
 
This peptide was assembled on Barlos resin (substitution 0.7 mmol/g) by automated 
solid phase peptide synthesis synthesizer as we describe in the general part (FastMoc 
Chemistry at 0.25 mmol scale).  
 
Ac- Gly-Ala-Arg(Pmc)-Lys(Boc)-Leu-OH  
 
The N-terminal protecting group was removed in the addition of 20% piperidine/DMF 
(10 mL) and kept for 30 min at room temperature. The acetylation was carried out in the 
solvent of DMF (5 mL) at the addition of NEt3 (0.25 mmol, 1 eq.) and Ac2O (0.25 mmol, 
1 eq.) to react 2 hours. The cleavage was processed following general part description. 
 
Ac-Gly-Ala-Arg(Pmc)-Lys(Boc)-Leu-Lys(Boc)-MCA 
 
Fmoc-Lys(Boc)-MCA (660 mg, 1 mmol) was dissolved in 20% piperidine/DMF (5 mL) 
and kept for 30 min at room temperature. After evaporation of piperidine and DMF, the 
residue was extracted with AcOEt, washed with sat. Na2CO3, dried over with anhydrous 
Na2CO3. The solution was concentrated to yield H-Lys(Boc)-MCA (404 mg, 1 mmol, 
yield 100%). 
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Ac-Gly-Ala-Arg(Pmc)-Lys(Boc)-Leu-OH (102 mg, 0.11 mmol) and H-Lys(Boc)-MCA 
(45 mg, 0.11 mmol) were dissolved in 2 mL DMF. To this chilled solution, HOBt.H2O 
(18 mg, 0.12 mmol, 1.1 eq.), HBTU (45 mg, 0.12 mmol, 1.1 eq.) and DIEA (0.02 mL, 
0.12 mmol, 1.1 eq.) were added. To react over 2 hours, TLC checked reaction 
completed. This compound was extracted with AcOEt, washed with 10% critic acid, 4% 
NaHCO3 and brine, dried over MgSO4. Filtration and evaporation of AcOEt gave 
desired compound (107 mg, 0.08 mmol, yield 74%). 
 
Ac-Gly-Ala-Arg-Lys-Leu-Lys-MCA (AcOH)3 
 
The removal side chain functional protecting groups of Ac-Gly-Ala-Arg(Pmc)- 
Lys(Boc)-Leu-Lys(Boc)-MCA (107 mg, 0.08 mmol) was carried out in the addition of 
TFA containing phenol (5%), thinanisole (5%), ethanedithiol (2.5%) and water (5%). 
The peptides were precipitated by dry ethyl ether. Crude peptides were purified by size 
exclusion chromatography performed on a borosilicate glass column filled with sephaex 
G-25 using 10% acetic acid in water as eluent. It gave 100% purity compound 42 mg, 
0.05 mmol. HR/MS (FAB) m/z calcd for [M+H]+ C41H67N12O9: 871.5076; found: 
871.5152. 
 
4-4-2-13 Synthesis of Ac-RKTK-MCA 
 
Synthesis of Fmoc-Arg(Pmc)-Lys(Boc)-Thr(tBu)-Barlos resin  
 
This peptide was assembled on Barlos resin (substitution 0.7 mmol/g) by manual solid 
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phase peptide synthesis as we described in the general part (0.25 mmol scale). 
 
Ac-Arg(Pmc)-Lys(Boc)-Thr(tBu)-OH 
 
The N-terminal protecting group was removed in the addition of 20% piperidine/DMF 
(5 mL) and kept for 30 min at room temperature. The acetylation was carried out in the 
solvent of DMF (5 mL) at the addition of NEt3 (0.25 mmol, 1 eq.) and Ac2O (0.25 mmol, 
1 eq.) to react 2 hours. The cleavage was processed following general part description. 
 
Ac-Arg(Pmc)-Lys(Boc)-Thr(tBu)-Lys(Boc)-MCA  
 
Ac-Arg(Pmc)-Lys(Boc)-Thr(tBu)-OH (146 mg, 0.17 mmol) and H-Lys(Boc)-MCA (68 
mg, 0.17 mmol) were dissolved in 2 mL DMF. To this chilled solution, HOBt.H2O (27 
mg, 0.18 mmol, 1.1 eq.), HBTU (68 mg, 0.18 mmol, 1.1 eq.) and DIEA (0.03 mL, 0.18 
mmol, 1.1 eq.) were added. To react over 2 hours, TLC checked reaction completed. 
This compound was extracted with AcOEt, washed with 10% critic acid, 4% NaHCO3 
and brine, dried over MgSO4. Filtration and evaporation of AcOEt gave desired 
compound (177 mg, 0.14 mmol, yield 83%). 
 
Ac-Arg-Lys-Thr-Lys-MCA (AcOH)3  
 
Ac-Arg(Pmc)-Lys(Boc)-Thr(tBu)-Lys(Boc)-MCA (100 mg, 0.08 mmol) was dissolved 
in a mixture of phenol/EDT/thioanisole/TFA/ water as 5/2.5/1/81.5/5 and allowed to 
stand at room temperature. After 1 hr, concentrated the solution and EtOtBu (20 mL) 
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was added to precipitate white material, which was collected by centrifugation and 
washed with same EtOtBu. The column chromatography was performed with G-25 25% 
AcOH. It gave 100% purity compound 44 mg, 0.06 mmol. HR/MS (FAB) m/z calcd for 
[M+H]+ C34H55N10O8: 731.4126; found: 731.4197. 
 
4-4-2-14 Synthesis of Ac-EARKTK-MCA 
 
Synthesis of Fmoc-Glu(OtBu)-Ala-Arg(Pmc)-Lys(Boc)-Thr(Trt)-Barlos resin 
 
This peptide was assembled on Barlos resin (substitution 0.7 mmol/g) by automated 
solid phase peptide synthesis synthesizer as we describe in the general part (FastMoc 
Chemistry at 0.25 mmol scale).  
 
Ac-Glu(OtBu)-Ala-Arg(Pmc)-Lys(Boc)-Thr(Trt)-OH  
 
The N-terminal protecting group was removed in the addition of 20% piperidine/DMF 
(5 mL) and kept for 30 min at room temperature. The acetylation was carried out in the 
solvent of DMF (5 mL) at the addition of NEt3 (0.25 mmol, 1.1 eq.) and Ac2O (0.25 
mmol, 1.1 eq.) to react 2 hours. The cleavage was processed following general part 
description. 
 
Ac-Glu(OtBu)-Ala-Arg(Pmc)-Lys(Boc)-Thr(Trt)-Lys(Boc)-MCA 
 
Fmoc-Lys(Boc)-MCA (660 mg, 1 mmol) was dissolved in 20% piperidine/DMF (5 mL) 
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and kept for 30 min at room temperature. After evaporation of piperidine and DMF, the 
residue was extracted with AcOEt, washed with sat. Na2CO3, dried over with anhydrous 
Na2CO3. The solution was concentrated to yield H-Lys(Boc)-MCA (400 mg, 1 mmol, 
yield 100%). 
 
Ac-Glu(OtBu)-Ala-Arg(Pmc)-Lys(Boc)-Thr(Trt)-OH (110 mg, 0.09 mmol) and 
H-Lys(Boc)-MCA (36 mg, 0.09 mmol) were dissolved in 2 mL DMF. To this chilled 
solution, HOBt.H2O (15 mg, 0.1 mmol, 1.1 eq.), HBTU (38 mg, 0.1 mmol, 1.1 eq.) and 
DIEA (0.015 mL, 0.1 mmol, 1.1 eq.) were added. To react over 2 hours, TLC checked 
reaction completed. This compound was extracted with AcOEt, washed with 10% critic 
acid, 4% NaHCO3 and brine, dried over MgSO4. Filtration and evaporation of AcOEt 
gave desired compound (98 mg, 0.06 mmol, yield 71%). 
 
Ac-Glu-Ala-Arg-Lys-Thr-Lys-MCA (AcOH)2 
 
The removal side chain functional protecting groups of Ac-Glu(OtBu)-Ala-Arg(Pmc)- 
Lys(Boc)-Thr(Trt)-Lys(Boc)-MCA (98 mg, 0.06 mmol) was carried out in the addition 
of TFA containing phenol (5%), thinanisole (5%), ethanedithiol (2.5%) and water (5%). 
The peptides were precipitated by dry ethyl ether. Crude peptides were purified by size 
exclusion chromatography performed on a borosilicate glass column filled with sephaex 
G-25 using 10% acetic acid in water as eluent. It gave 100% purity compound 37 mg, 
0.04 mmol. HR/MS (FAB) m/z calcd for [M+H]+ C42H67N12O12: 931.4923; found: 
931.5050. 
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4-4-2 Assay 
 
The assay for measuring HMTs activity was carried out as followed. 
 
4-4-2-1 Activity of G9a 
 
Ten L of 2 × HMT buffer (100 mM Tris-HCl (pH 8.5), 20 mM MgCl2, 40 mM KCl, 
20 mM 2-mercaptoethanol, 500 mM sucrose), 0.4 L of a BSA solution (150 g/mL), 
4.5 L of GST-mG9a (0, 0.022 to 0.66 g/L), and 1.1 L of distilled water were 
mixed and then incubated at room temperature for 1 hour. Then, 2 L of SAM (10 mM) 
and 2 L of a peptide MCA solution (0.6 mM) were added thereto, which was then 
incubated at 37oC for 1 hour. Thereafter, 30 L of a trypsin solution (20 mg/mL) was 
added thereto, followed by incubation at 37oC for 15 min. Then, the fluorescence 
intensity of the solution was measured at an excitation wavelength (ex) of 390 nm and 
a fluorescence wavelength (em) of 460 nm. The final concentration of GST-mG9a 
during the measurement of fluorescence intensity was 0, 0.005, 0.015, 0.05, or 0.15 
g/L. 
 
4-4-2-2 Activity of Set7/9  
 
Ten L of 2 × HMT buffer (100 mM Tris-HCl (pH 8.5), 20 mM MgCl2, 40 mM KCl, 
20 mM 2-mercaptoethanol, 500 mM sucrose), 2 L of a BSA solution (30 g/mL), 3 L 
of His-Set7/9 (0, 0.33 to 10 g/L), and 1 L of distilled water were mixed and then 
incubated at room temperature for 1 hour. Then, 2 L of SAM (10 mM) and 2 L of a 
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peptide MCA solution (0.6 mM) were added thereto, which was then incubated at 37oC 
for 1 hour. Thereafter, 30 L of a trypsin solution (20 mg/mL) was added thereto, 
followed by incubation at 37oC for 15 min. Then, the fluorescence intensity of the 
solution was measured at an excitation wavelength (ex) of 390 nm and a fluorescence 
wavelength (em) of 460 nm. The final concentration of His-Set7/9 during the 
measurement of fluorescence intensity was 0, 0.005, 0.015, 0.05, or 0.15 g/L.  
 
The assay for measuring HMTs inhibitor activity was carried out as followed. 
Gliotoxin is known not to inhibit the methylation activity of Set7/9 but to inhibit the 
methylation activity of G9a. The S-Adenosyl-L-homocysteine (SAH) which is a 
by-product of the methylation reaction and is known to inhibit HMT in a negative 
feedback manner, also been used to replace gliotoxin.  
 
4-4-2-3 Inhibition of G9a  
 
Ten L of 2 × HMT buffer (100 mM Tris-HCl (pH 8.5), 20 mM MgCl2, 40 mM KCl, 
20 mM 2-mercaptoethanol, 500 mM sucrose), 0.4 L of a BSA solution (150 g/mL), 2 
L of GST-mG9a (0, 0.5 g/L), 1 L of gliotoxin (any of various concentrations) and 
2.6 L of distilled water were mixed and then incubated at room temperature for 1 hour. 
Then, 2 L of SAM (10 mM) and 2 L of a peptide-MCA (Ac-histone H3 (1-9)-MCA) 
solution (0.6 mM) were added thereto, which was then incubated at 37oC for 1 hour. 
Thereafter, 30 L of a trypsin solution (20 mg/mL) was added thereto, followed by 
incubation at 37oC for 15 min. Then, the fluorescence intensity of the solution was 
measured at an excitation wavelength (ex) of 390 nm and a fluorescence wavelength 
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(em) of 460 nm. The final concentration of GST-mG9a during the measurement of 
fluorescence intensity was 0.05 g/L. 
 
4-4-2-4 Inhibition of Set7/9  
 
Ten L of 2 × HMT buffer (100 mM Tris-HCl (pH 8.5), 20 mM MgCl2, 40 mM KCl, 
20 mM 2-mercaptoethanol, 500 mM sucrose), 0.4 L of a BSA solution (150 g/mL), 
4.5 L of His-Set7/9 (0, 2.25 g/L), 1 L of gliotoxin (any of various concentrations) 
and 2.6 L of distilled water were mixed and then incubated at room temperature for 1 
hour. Then, 2 L of SAM (10 mM) and 2 L of a peptide-MCA (Ac-p53 
(369-372)-MCA) solution (0.6 mM) were added thereto, which was then incubated at 
37oC for 1 hour. Thereafter, 30 L of a trypsin solution (20 mg/mL) was added thereto, 
followed by incubation at 37oC for 15 min. Then, the fluorescence intensity of the 
solution was measured at an excitation wavelength (ex) of 390 nm and a fluorescence 
wavelength (em) of 460 nm. The final concentration of GST-mG9a during the 
measurement of fluorescence intensity was 0.05 g/L.  
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4-5 Results and discussion 
 
We discovered that Ac-ARTKQTARK-MCA, the longest peptide is the most specific 
and susceptible substrate of G9a. However, Set7/9 methylated moderately histone 
tail-related Ac-peptide-MCA, but showed higher activity to p53 and Estrogen Receptor 
-sequences; Ac-KRSK-MCA from ER was the best substrates of Set7/9. Thus, we 
confirmed the substrate specificities of HMTs regarding the amino acid sequences. This 
assay system could be applied for further understanding of various HMTs. (Fig. 5 and 6) 
 
In addition, we carried out the evaluation of gliotoxin, a known G9a inhibitor by new 
assay procedure using Ac-ARTKQTARK-MCA and obtained 2.8 M as Ki value, close 
to the reported value 2.0 M. When Ac-LKSK-MCA was used to examine the Set7/9 
inhibition by gliotoxin, this compound showed no inhibitory activity (>100 M) 
suggesting specific inhibition of G9a.  
 
Since It is also known that S-(5’-Adenosyl)-L-homocystein (SAH), another product of 
methylation reaction, is an inhibitor of HMTs as negative feedback, we determined its 
inhibitory activity by this assay procedure. The IC50 of 0.49 mM was obtained for G9a.  
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Fig. 5. The assay for HMT activity using peptide-MCA base on histone tail. 
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Fig. 6. The assay for HMT activity using peptide-MCA base on histone tail. 
 96 
 
 
 
0
20
40
60
80
100
120
140
0 0.02 0.04 0.06 0.08 0.1 0.12 0.14 0.16
GST-mG9a (g / L)
U
n
m
e
th
y
la
te
d
 p
e
p
ti
d
e
-M
C
A
(%
 o
f 
c
o
n
tr
o
l)
G9a / peptide-MCA
 
0
20
40
60
80
100
120
0 0.1 0.2 0.3 0.4 0.5 0.6
His-Set7/9 (g / L)
Set7/9 / peptide-MCA
U
n
m
e
th
y
la
te
d
 p
e
p
ti
d
e
-M
C
A
 
(%
 o
f 
c
o
n
tr
o
l)
 
 
Fig. 6. The assay for HMT activity using peptide-MCA base on histone tail. 
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Chapter 5  
 
New fluorescence-measuring-instrument - EAAS-PD 
 
5-1 Introduction 
 
In recent decades, fluorescence measuring instrument have been used widely in the 
areas such as medical diagnoses, environmental evaluations, and monitoring operations 
in detection systems in which a fluorescence intensity is successively increased by a 
chemical reaction. By the developing of electronic and manufacturing, many of the 
companies and institutes are worked on the studies of fluorescence detection device, 
here we summaries some device are classical and mentioned a lot. For example, a patent 
name is “method for measuring enzyme activity, and device for the same using laser”, 
which is an enzyme activity measurement device at least including a laser light source 
for near-infrared femtosecond laser light for inducing a process of multiphoton 
excitation of a substrate or a product of substrate metabolism, a radiation wave detection 
part that detects radiation wave generated from the process of multiphoton excitation of 
the substrate or the product of substrate metabolism; and an optical path that guides the 
near-infrared femtosecond laser light to a site where an enzyme exists and guides the 
radiation wave to the radiation wave detection part; from the company Olympus 
Corporation, the patent named “fluorescence measuring device” which is a fluorescence 
measurement device including a light source for exciting a fluorescence substance in a 
sample, a collecting lens that collects fluorescence emitted from the fluorescence 
substance, a spatial filter that transmits the fluorescence collected by the collecting lens, 
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an photodetector that detects the fluorescence that has passed through the spatial filter, a 
signal analysis part that analyzes an output signal from the photodetector, and an 
adjustment part that adjusts an arrangement position of at least one of the collecting lens 
and the spatial filter based on an analysis result obtained by the signal analysis part. The 
all been developed in twentieth century and concerned to people’s life. 
 
The conventional fluorescence measurement devices that already developed each 
consist of a complicated configuration and are expensive, also they are just have been 
proved useful in the research field, but they are not assumed to be used on the clinic 
level. Furthermore, when systems using optical fibers, problems inherent to fibers such 
as end face loss, joint loss and the problem of the material for the ultraviolet region 
cannot be ignored. In particular, in the case of guiding from the bottom portion by a 
fiber, many problems may occurs in consideration of irradiation end face joint structure, 
dirt on the measurement spot bottom portion and numerical aperture of the optical fiber 
as well as material deterioration due to short wavelength.  
 
5-2 Target 
 
In order to apply as tools for connection between a dentist and a patient, inexpensive 
and simple fluorescence measurement devices are indispensable. We provided a 
fluorescence measurement device that are provided by a simpler structure, more 
inexpensive and capable of measuring an amount of fluorescence using a very small 
amount of sample.  
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5-3 Design 
 
 
  
 
 
Fig. 1. The front and side views of fluorescence detector. It contains sample holder 
(bottom), fluorescence detector (middle), and data processor (top).  
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Using a fluorescence measurement device including a light-blocking measurement box 
to which a microtube is loaded; a container support part disposed inside the 
measurement box, the container support part vertically supporting the microtube; (Fig. 1) 
an excitation light source part disposed inside the measurement box, the excitation light 
source part including a light source that horizontally irradiates excitation light a 
sidewall surface of the loaded microtube; and a fluorescence detection part provided at 
an upper portion of the measurement box and above the loaded microtube, the 
fluorescence detection part measuring an amount of fluorescence in a particular 
wavelength range from a target sample, a microtube charged with a target liquid sample 
is loaded into the measurement box, the microtube that is uncapped is irradiated 
laterally in a horizontal direction with excitation light having a particular peak 
Photodetector
Filter （442 nm）
Microtube 
（1.5 mL, SARSTEDT)
Substrate solution  （100 L）
LED light source （365 nm）
Heater
 
Fig. 2. The instrument structure schematic diagram and the photo of microtube.  
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wavelength, and an amount of fluorescence from the target liquid sample excited by 
light distributed to the entire region of the target liquid inside the tube using a sidewall 
surface of the microtube as an excitation light waveguide and light leaking from the 
sidewall surface is measured by a fluorescence detection part for a particular 
wavelength range. (Fig. 2) 
 
5-4 Experimental 
 
By dissolving HEPES buffer of 0.1M, pH 7.2 to the AMC, and to prepare the 1 ~ 10 μM 
solution, using a fluorescence measurement device to set the condition for radiating 
light having a peak of 365 nm ± 10 nm, receiving at 442 nm, and the fluorescence 
intensity was measured.  
 
5-5 Results and discussion 
 
We got the result that a substantially linear relationship was indicated between the 
fluorescence intensity and the AMC concentration. (Fig. 3) The results indicate that the 
present invention enables sensing fluorescence from AMC with a high sensitivity to 
measure the AMC concentration. The more applications will be described in next 
chapter. 
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Fig. 3. The concentration of AMC fluorescence intensity and showed a linear 
relationship substantially. 
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Chapter 6  
 
Fluorescent substrates of Arg-gingipain for periodontal diseases 
 
6-1 Introduction 
 
With the great progress of microbiology and immunology, the understanding of 
periodontal etiology and pathogenesis unceasingly develops and perfects. Periodontal 
disease is caused by plague bacteria infection process, some bacteria can indeed cause 
periodontal disease also has been confirmed. [1-7] Now, it is more and more important 
to accurately grasp the periodontopathic bacteria to diagnosis the periodontal disease 
and therapy options. [8] Among the several hundreds of different plaque-associated 
bacterial species, these three kinds of bacteria Actinobacillus actinomycetemcomitans, 
Porphyromonas gingivalis and Tannerella forsythensis are known as the most powerful 
periodontal pathogens. [4, 5] Normally bacterial culture is the most traditional method 
to detect bacteria. [9] With the developing of biotechnology, Enzyme-Linked Immuno 
Sorbent Assay (ELISA), DNA probe technology and Polymerase Chain Reaction (PCR) 
are all applied to confirm the plaque bacteria. [10-13] But they all cannot get result in 
short time even take several weeks, or some of them need professional technical and 
sophisticated high cost instrument. It is looking forward one kind of novel assay which 
can detect highly progressive of periodontal and quickly display the results. To solve the 
above-described problems, one kind bacterial enzyme detection Benzoyl-Argine 
Naphthylamide (BANA) was established. Accompanied the inflammation caused by A. 
actinomycetemcomitans, P. gingivalis and T. forsythensis, the leukocyte elastase activity 
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will be increased in the periodontal tissue. To detect the synthetic substrate BANA that 
hydrolyzed by the enzyme, the assay of periodontal could be understood. The sensitivity, 
specificity and accuracy of this BANA method could achieve around 80%. [14, 15] 
 
6-2 Target 
 
Periodontitis as one of the oldest and most general disease in the history of human being 
have been understated that almost all periodontal diseases are caused by the infection of 
plaque bacteria. Arg-gingipain is one of the major cysteine proteinases produced by the 
oral anaerobic bacterium Porphyromonas gingivalis, which has been shown to act as 
major pathogen in the development and progression of periodontal diseases. We target 
to one highly sensitive fluorescent assay using a novel fluorescently labeled peptide 
sequence. This assay has been used for the detection of periodontitis activity, the plaque 
bacteria and the antibody of inflammatory cell. This could help the developing the 
prophylaxis and therapeutic agents of oral healthy.  
 
6-3 Design 
 
We developed novel synthetic fluorescent substrate peptide-7-amino-4-methylcoumarin, 
which had the cytotoxic activity to neutrophils inflammatory cells, easily decomposed 
by periodontal tissue collagen and it also had the activity to the specific disintegration 
of arginylendopeptidase. This assay will be a powerful tool for oral health of 
periodontal and drug lead identification and characterization. 
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6-4 Experimental 
 
6-4-1 Synthesis  
 
General 
 
Unless otherwise noted, all solvents and reagents were reagent grade obtained from 
WAKO, Japan. Flash chromatography was performed using silica gel 60 (230–400 mesh) 
eluting with solvents as indicated. All compounds were routinely checked by thin layer 
chromatography (TLC) and/or high performance liquid chromatography (HPLC). TLC 
was performed on aluminum-backed silica gel plates (Merck DC-Alufolien Kieselgel 60 
F254) with spots visualized by UV light or charring. Analytical HPLC was performed on 
a Hitachi instrument equipped with a chromolith performance RP-18e column (4.6 × 
100 mm, Merck). The mobile phases used were A: H2O with 0.1% TFA, B: CH3CN 
with 0.1% TFA using a solvent gradient of A-B over 15 min with a flow rate of 2 
mL/min, with detection at 220 nm. HR FAB-mass spectra were measured on a JEOL 
JMS-SX 102A instrument.   
 
6-4-1-1 Synthesis of iBoc-GGR-MCA 
 
Synthesis iBoc-Gly-Gly-OH 
 
Dissolved Gly-Gly-OH (13.2 g, 100 mmol) using 2 M NaOH solution (110 mL) in 300 
mL flask completed, then used ice bath to cool down. To this solvent, added 20 mL 
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ether and vigorously stirred, then added isobutyl chloroformate (IBCF, 15.6 mL, 120 
mmol) dropwise in 1 hour. To confirm the pH of this solvent up to 9, stirred this 
reaction 1 hour in room temperature. 
 
Added more ether 100 mL, removed them to the separatory funnel. Separated water 
layer, washed ether layer by 4% NaHCO3, combine the 4% NaHCO3 with the former 
water layer, adjusted pH of this solvent at 3 by 1 M HCl solution. Extracted desired 
compound by ether acetate (200 mL), confirmed by TLC (chloroform/methanol 9/1, 
v/v). Washed this solution with brine and dried over MgSO4. To filtrate and evaporate 
the AcOEt and the residues were crystallized in ether; it gave solid compound (18.4 g, 
yield 80%). 
 
Synthesis Fmoc-Arg(Pmc)-MCA 
 
Dissolved Fmoc-Arg(Pmc)-OH･IPE (0.61 g, 8 mmol) completely in dichloromethane 
(DCM, 15 mL), to this solution dicyclohexylcarbodiimide (DCC, 0.62 g, 3 mmol) was 
added and stirred 1 hour. 7-amino-4-methylcoumarin (AMC, 0.88 g, 5 mmol) was 
added to react 30 min, then added DCC (0.62 g, 3 mmol) to react overnight. TLC and 
HPLC confirmed reaction finished, the solution was concentrated and the residues were 
crystallized in chloroform; it gave solid compound 2.4 g, yield 59%. 
 
Synthesis of iBoc-Gly-Gly-Arg(Pmc)-MCA 
 
Fmoc-Arg(Pmc)-MCA (1.64 g, 2 mmol) dissolved in 20% piperidine/dimethyl 
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formamide (DMF) 10 mL and kept for 30 min at room temperature. After evaporation of 
piperidine and DMF, the residue was extracted with AcOEt, washed with sat. Na2CO3, 
dried over with anhydrous Na2CO3. The solution was concentrated to yield 
H-Arg(Pmc)-MCA. Dissolved this compound in 4 mL DMF then added 
iBoc-Gly-Gly-OH in ice bath accompany with HOBt･H2O (0.31 g, 2 mmol), DCC (0.50 
g, 2.4 mmol) to stirred overnight. HPLC to confirmed reaction finished, then solution 
was concentrated and the residue was extracted to AcOEt, washed with 10% critic acid, 
4% NaHCO3 and brine, dried over with MgSO4. The solution was concentrated and the 
residues were applied to a silica gel column using a mixture of methanol/chloroform 
(1:49) to get the desire compound iBoc-Gly-Gly-Arg(Pmc)-MCA 0.75 g which could be 
crystallized in ether. 
 
Synthesis of iBoc-Gly-Gly-Arg(Pmc)-MCA･AcOH 
 
iBoc-Gly-Gly-Arg(Pmc)-MCA was dissolved in trifluoroacetic acid (TFA, 5 mL) and 
allowed to stand at room temperature. After 1 hr, concentrated the solution and EtOtBu 
(20 mL) was added to precipitate white material, which was collected by centrifugation 
and washed with same EtOtBu. The column chromatography (1.8 × 70 cm, 25% AcOH) 
was performed with Sephadex G-25. The desire compound was collected, concentrated, 
and prepared for lyophilization. It gave 100% purity iBoc-GGR-MCA･AcOH 130 mg, 
yield 94%. HR-FAB-MS [M+H]+ 546.2686 for C25H36N7O7 (calcd 546.2676). 
 
6-4-1-2 Synthesis of iBoc-FSR-MCA 
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Synthesis of iBoc-Phe-OH 
 
Dissolved Phe-OH (3.3 g, 20 mmol) using 2 M NaOH solution (24 mL) in 200 mL flask 
completed, then used ice bath to cool down. To this solvent, added 4 mL ether and 
vigorously stirred, then added isobutyl chloroformate (IBCF, 3.12 mL, 24 mmol) 
dropwise in 1 hour. To confirm the pH of this solvent up to 9, stirred this reaction 1 hour 
in room temperature. 
 
Added more ether 50 mL, removed them to the separatory funnel. Separated water layer, 
washed ether layer by 4% NaHCO3, combine the 4% NaHCO3 with the former water 
layer, adjusted pH of this solvent at 3 by 1 M HCl solution. Extracted desired compound 
by ether acetate (50 mL), confirmed by TLC (chloroform/methanol 9/1, v/v). Washed 
this solution with brine and dried over MgSO4. To filtrate and evaporate the AcOEt and 
the residues were crystallized in ether; it gave solid compound (4.5 g, yield 85%). 
 
Synthesis of Fmoc-Arg(Pmc)-MCA 
 
Dissolved Fmoc-Arg(Pmc)-OH･IPE (0.61 g, 8 mmol) completely in dichloromethane 
(DCM, 15 mL), to this solution dicyclohexylcarbodiimide (DCC, 0.62 g, 3 mmol) was 
added and stirred 1 hour. 7-amino-4-methylcoumarin (AMC, 0.88 g, 5 mmol) was 
added to react 30 min, then added DCC (0.62 g, 3 mmol) to react overnight. TLC and 
HPLC confirmed reaction finished, the solution was concentrated and the residues were 
crystallized in chloroform; it gave solid compound 2.4 g, yield 59%. 
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Synthesis of Fmoc-Ser(tBu)-Arg(Pmc)-MCA 
 
Fmoc-Arg(Pmc)-MCA (0.8 g, 1 mmol) dissolved in 20% piperidine/dimethyl 
formamide (DMF) 5 mL and kept for 30 min at room temperature. After evaporation of 
piperidine and DMF, the residue was extracted with AcOEt, washed with sat. Na2CO3, 
dried over with anhydrous Na2CO3. The solution was concentrated to yield 
H-Arg(Pmc)-MCA. Dissolved this compound in 2 mL DMF then added 
Fmoc-Ser(tBu)-OH (0.64 g, 1.2 mmol) in ice bath accompany with HOBt･H2O (0.15 g, 
1 mmol), HBTU (0.38 g, 1 mmol) and DIEA (0.17 mL, 1 mmol) to stirred 2 hours. 
HPLC to confirmed reaction finished, then solution was concentrated and the residue 
was extracted to AcOEt, washed with 10% critic acid, 4% NaHCO3 and brine, dried 
over with MgSO4. The solution was concentrated and the residues were applied to a 
silica gel column using a mixture of methanol/chloroform (1:49) to get the desire 
compound Fmoc-Ser(tBu)-Arg(Pmc)-MCA 0.82 g. 
 
Synthesis of iBoc-Phe-Ser(tBu)-Arg(Pmc)-MCA 
 
Fmoc-Ser(tBu)-Arg(Pmc)-MCA (0.82 g, 0.85 mmol) dissolved in 20% 
piperidine/dimethyl formamide (DMF) 5 mL and kept for 30 min at room temperature. 
After evaporation of piperidine and DMF, the residue was extracted with AcOEt, 
washed with sat. Na2CO3, dried over with anhydrous Na2CO3. The solution was 
concentrated to yield H-Ser(tBu)-Arg(Pmc)-MCA. Dissolved this compound in 2 mL 
DMF then added iBoc-Phe-OH (0.64 g, 1.2 mmol) in ice bath accompany with HOBt･
H2O (0.15 g, 1 mmol), HBTU (0.38 g, 1 mmol) and DIEA (0.17 mL, 1 mmol) to stirred 
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2 hours. HPLC to confirmed reaction finished, then solution was concentrated and the 
residue was extracted to AcOEt, washed with 10% critic acid, 4% NaHCO3 and brine, 
dried over with MgSO4. The solution was concentrated and the residues were applied to 
a silica gel column using a mixture of methanol/chloroform (1:49) to get the desire 
compound Fmoc-Ser(tBu)-Arg(Pmc)-MCA 0.75 g which could be crystallized in ether. 
 
Synthesis of iBoc-Phe-Ser-Arg-MCA･AcOH 
 
iBoc-Phe-Ser(tBu)-Arg(Pmc)-MCA was dissolved in the mixture 
Phenol/EDT/Thioanisole/TFA/H2O, (0.75/0.25/0.5/10/0.5) and allowed to stand at room 
temperature. After 2 hour, concentrated the solution and EtOtBu (20 mL) was added to 
precipitate white material, which was collected by centrifugation and washed with same 
EtOtBu. The column chromatography (1.8 × 70 cm, 25% AcOH) was performed with 
Sephadex G-25. The desire compound was collected, concentrated, and prepared for 
lyophilization. It gave 100% purity iBoc-FSR-MCA･AcOH 650 mg, yield 90%. 
HR-FAB-MS [M+H]+ 628.9951 for C33H44N7O8 (calcd 628.3251). 
 
6-4-1-3 Synthesis of iBoc-VPR-MCA 
 
Synthesis of iBoc-Val-OH 
 
Dissolved Val-OH (2.3 g, 20 mmol) using 2 M NaOH solution (24 mL) in 200 mL flask 
completed, then used ice bath to cool down. To this solvent, added 4 mL ether and 
vigorously stirred, then added isobutyl chloroformate (IBCF, 3.12 mL, 24 mmol) 
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dropwise in 1 hour. To confirm the pH of this solvent up to 9, stirred this reaction 1 hour 
in room temperature. 
  
Added more ether 50 mL, removed them to the separatory funnel. Separated water layer, 
washed ether layer by 4% NaHCO3, combine the 4% NaHCO3 with the former water 
layer, adjusted pH of this solvent at 3 by 1 M HCl solution. Extracted desired compound 
by ether acetate (50 mL), confirmed by TLC (chloroform/methanol 9/1, v/v). Washed 
this solution with brine and dried over MgSO4. To filtrate and evaporate the AcOEt and 
the residues were crystallized in ether; it gave solid compound (4.1 g, yield 92%). 
 
Synthesis of Fmoc-Arg(Pmc)-MCA 
 
Dissolved Fmoc-Arg(Pmc)-OH･IPE (0.61 g, 8 mmol) completely in dichloromethane 
(DCM, 15 mL), to this solution dicyclohexylcarbodiimide (DCC, 0.62 g, 3 mmol) was 
added and stirred 1 hour. 7-amino-4-methylcoumarin (AMC, 0.88 g, 5 mmol) was 
added to react 30 min, then added DCC (0.62 g, 3 mmol) to react overnight. TLC and 
HPLC confirmed reaction finished, the solution was concentrated and the residues were 
crystallized in chloroform; it gave solid compound 2.4 g, yield 59%. 
  
Synthesis of Fmoc-Phe-Arg(Pmc)-MCA 
 
Fmoc-Arg(Pmc)-MCA (0.8 g, 1 mmol) dissolved in 20% piperidine/dimethyl 
formamide (DMF) 5 mL and kept for 30 min at room temperature. After evaporation of 
piperidine and DMF, the residue was extracted with AcOEt, washed with sat. Na2CO3, 
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dried over with anhydrous Na2CO3. The solution was concentrated to yield 
H-Arg(Pmc)-MCA. Dissolved this compound in 2 mL DMF then added Fmoc-Pro-OH 
(0.4 g, 1.2 mmol) in ice bath accompany with HOBt･H2O (0.15 g, 1 mmol), HBTU 
(0.38 g, 1 mmol) and DIEA (0.17 mL, 1 mmol) to stirred 2 hours. HPLC to confirmed 
reaction finished, then solution was concentrated and the residue was extracted to 
AcOEt, washed with 10% critic acid, 4% NaHCO3 and brine, dried over with MgSO4. 
The solution was concentrated and the residues were applied to a silica gel column 
using a mixture of methanol/chloroform (1:49) to get the desire compound 
Fmoc-Phe-Arg(Pmc)-MCA 0.82 g. 
  
Synthesis of Fmoc-Val-Pro-Arg(Pmc)-MCA 
 
Fmoc-Pro-Arg(Pmc)-MCA (0.82 g, 0.85 mmol) dissolved in 20% piperidine/dimethyl 
formamide (DMF) 5 mL and kept for 30 min at room temperature. After evaporation of 
piperidine and DMF, the residue was extracted with AcOEt, washed with sat. Na2CO3, 
dried over with anhydrous Na2CO3. The solution was concentrated to yield 
H-Pro-Arg(Pmc)-MCA. Dissolved this compound in 2 mL DMF then added 
iBoc-Val-OH (0.64 g, 1.2 mmol) in ice bath accompany with HOBt･H2O (0.15 g, 1 
mmol), HBTU (0.38 g, 1 mmol) and DIEA (0.17 mL, 1 mmol) to stirred 2 hours. HPLC 
to confirmed reaction finished, then solution was concentrated and the residue was 
extracted to AcOEt, washed with 10% critic acid, 4% NaHCO3 and brine, dried over 
with MgSO4. The solution was concentrated and the residues were applied to a silica gel 
column using a mixture of methanol/chloroform (1:49) to get the desire compound 
Fmoc-Val-Pro-Arg(Pmc)-MCA 0.75 g which could be crystallized in ether. 
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Synthesis of iBoc-Val-Pro-Arg-MCA･AcOH 
 
iBoc-Val-Pro-Arg(Pmc)-MCA was dissolved in the mixture Phenol/EDT/Thioanisole/ 
TFA/H2O, (0.75/0.25/0.5/10/0.5) and allowed to stand at room temperature. After 2 hour, 
concentrated the solution and EtOtBu (20 mL) was added to precipitate white material, 
which was collected by centrifugation and washed with same EtOtBu. The column 
chromatography (1.8 × 70 cm, 25% AcOH) was performed with Sephadex G-25. The 
desire compound was collected, concentrated, and prepared for lyophilization. It gave 
100% purity iBoc-VPR-MCA･AcOH 650 mg, yield 90%. HR-FAB-MS [M+H]+ 
628.3818 for C31H46N7O7 (calcd 628.3459). 
 
6-4-2 Assay 
 
6-4-2-1 Measurement of the fluorescence intensity associating with 
trypsin concentration 
 
iBoc-Gly-Gly-Arg-MCA was dissolved in a 0.1 M HEPES buffer with a pH of 7.2 and 
100 μL of the resulting solution was charged into a microtube (A-1500), and 5 μL of a 
trypsin solution with an adjusted concentration was added and then fluorescence 
intensity measurement was conducted for ten minutes to obtain differences in 
fluorescence intensity ΔFI for the ten minutes. Where the ΔFI-trypsin concentration 
relationship was plotted, a linear correlation was obtained.  
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6-4-2-1 Measurement of the fluorescence intensity associating with 
periodontal pocket depth  
 
iBoc-Gly-Gly-Arg-MCA was dissolved in a 0.1 M HEPES buffer with a pH of 7.2 and 
100 μL of the resulting solution was charged into a microtube (A-1500), 0.1 μL of 
gingival effusion of a patient with a periodontal disease was obtained via a paper point 
and this was used as a sample and added into the iBoc-Gly-Gly-Arg-MCA solution 
inside the microtube. Fluorescence intensity measurement was conducted for ten 
minutes, and differences in fluorescence intensity ΔFI for the ten minutes were plotted 
relative to periodontal pockets (pocket depth: PD) measured by a dentist.  
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6-5 Results and discussion 
 
It was confirmed that according to the help of EAAS-PD, a rate for trypsin to cut AMC 
out using iBoc-Gly-Gly-Arg-MCA as a substrate can be measured from a rise in AMC 
concentration. (Fig. 1.) 
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Fig. 1. The results of fluorescence intensity measurements made in a set condition in 
which using the EAAS-PD, trypsin was made to act on a substrate solution which 
was then irradiated with light having a peak in a range of 365 nm  10 nm and light 
of 442 nm was received. 
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It was also confirmed that an enzyme activity of the enzyme Arg-gingipain produced by 
P. gingivalis, which is a periodontal disease-causing bacterium, Arg-gingipain having an 
ability of cutting AMC out, in gingival effusion is measured to determine whether or not 
the periodontal disease is in an active phase, which is effective for formulating a 
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Fig. 2. The results of fluorescence intensity measurements made in a set condition in 
which using the fluorescence measurement device EAAS-PD, a gingival effusion 
from a patient with a periodontal disease was made to act on a substrate solution 
which was then irradiated with light having a peak in a range of 365 nm  10 nm and 
light of 442 nm was received. 
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therapeutic strategy. (Fig. 2) 
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Chapter 7 
 
 Conclusions 
 
A series of Ac-Lys(X)-MCA was successfully synthesized. Some of the non-natural acyl 
groups have been shown to be more susceptible than Ac group to HDACs. Substrate 
form cortactin Ac-KGFGGK(Ac)-MCA was successfully used for measuring HDAC 
activity.  
 
The procedure to prepare Fmoc-L-Lys(Boc, Me)-OH and Fmoc-L-Lys(Me)2-OH had 
been developed. These amino acids were applied to synthesize Ac-ARTK(Me)-MCA 
and Ac-ARTK(Me)2-MCA. 
 
We successfully synthesized various Ac-peptide-MCA with Lys at the C-termini 
learning from the amino acid sequences of histone tail peptide and some proteins which 
are known as HMT substrates. 
 
We discovered that Ac-ARTKQTARK-MCA, the longest peptide is the most specific 
and susceptible substrate of G9a. Ac-KRSK-MCA from ER was the best substrates of 
Set7/9. This assay system could be applied for further understanding of various HMTs. 
 
This high through put out screening system also could be used for understanding 
various HMT inhibitors, gliotoxin known as a G9a inhibitor was carried out for 
evaluation using the sequence which was selected from peptide-MCA: Ac-histone H3 
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(1-9)-MCA (Ac-ARTKQT-ARK-MCA). We obtained 2.1 M as IC50 value close to the 
Elisa determined value (2.0 M).  
 
One product in methylation reaction S-(5’-Adenosyl)-L-homocystein (SAH) an 
inhibitor of HMTs as negative feedback, was determined by this screening procedure. 
The IC50 of 0.49 mM was obtained for G9a. It is the first time to understand in the 
world of HMT s inhibitors.  
 
We developed one fluorescence measuring device, which is sensitive but simpler, 
cheaper than the commercial ones, had the development potential for the application in 
the clinic. We applied this new device for determining the periodontal pocket depth in 
the new substrates that we designed.  
  
The new device to measure the periodontal disease not only to prove the useful of the 
new instrument but also provide one new substrate was developed. 
 125 
 
Acknowledgements 
 
I would like to thank my supervisor Professor Norikazu Nishino and Professor Tamaki 
Kato (Kyushu Institute of Technology) for sharing their knowledge, experience and 
expertise selflessly. They provided me the rare opportunity to learn not only the 
experiment but also the living philosophy that will be the treasure of my life.  
 
I express my sincere gratitude to Akihiro Ito and Professor Minoru Yoshida for the 
analysis of our compounds. 
 
To give my heartiest thanks to the present and past members of Nishino & Kato 
laboratory especially Professor Li Xiaohui and Doctor Tienabe K. Nsiama for their 
co-operation, encouragement and discussion.  
 
Cordial thanks to the people of Japan for providing me financial support. 
 
Finally, I would like to thank my family they are my inspiration throughout my life. 
 
Chi Hongfang 
Department of Biological Functions and Engineering 
Graduate School of Life Science and Systems Engineering 
Kyushu Institute of Technology 
Kitakyushu, 808-0196 
Japan 
 126 
 
List of publication 
 
1. Design and synthesis of peptide-MCA substrates for a novel assay of histone 
methyltransferases and their inhibitors. 
Hongfang Chi, Yasushi Takemoto, Tienabe K. Nsiama, Tamaki Kato, Norikazu 
Nishino, Akihiro Ito and Minoru Yoshida. Bioorganic & Medicinal Chemistry 2014, 
22, 1268-1275. 
2. A convenient preparation of N ε-methyl-l-lysine derivatives and its application to 
the synthesis of histone tail peptides.  
Hongfang Chi, Md. Shahidul Islam, Tienabe K. Nsiama, Tamaki Kato, and 
Norikazu Nishino. Amino Acids 2014, February, on line publication. 
3. Dynamics and regulation of lysine-acetylation during one-cell stage mouse 
embryos. 
Keigo Matsubara, Ah Reum Lee, Satoshi Kishigami, Akio Ito, Kazuya Matsumoto, 
Hongfang Chi, Norikazu Nishino, Minoru Yoshida, and Yoshihiko Hosoi. 
Biochemical and Biophysical Research Communications, 2013, 434, 1-7. 
4. High Through Put Screening System for Histone Methyltransferase Inhibitors. 
Hongfang Chi, Norikazu Nishino, Tienabe K. Nsiama, Yasushi Takemoto, Akihiro 
Ito, Minoru Yoshida. Peptide Science: Proceedings of the 5th International Peptide 
Symposium 2011, 264 
5. Assay of Histone Methyltransferases using Ac-Peptidyl-MCA as Substrates. 
Norikazu Nishino, Tienabe K. Nsiama, Hongfang Chi, Yasushi Takemoto, Akihiro 
Ito, and Minoru Yoshida. Peptides 2010: Proceedings of the 31st European Peptide 
Symposium 2010, 480. 
 127 
 
6. Thirteen-membered Cyclic Tetrapeptides as Histone Deacetylase Inhibitors. 
Hongfang Chi, Yasuhiko Otsuka, Tamaki Kato, Norikazu Nishino, Nobuyuki 
Kobashi, Akihiro Ito, and Minoru Yoshida. Peptides: Proceedings of the 11th 
Chinese International Peptide Symposium 2010, 177-181. 
7. Convenient Preparation of N-Methyl-L-Lysine and Incorporation to Histone Tail 
Peptides. Hongfang Chi, Md. Shahidul Islam, Tienabe K. Nsiama, Tamaki Kato, 
and Norikazu Nishino. Peptide Science 2009: Proceedings of the 46th Japanese 
Peptide Symposium 2010, 137-140. 
 
 128 
 
Presentations at conferences 
 
1. Poster presentation: “Sequence Dependency in Cyclization Reaction for Cyclic 
Tetrapeptides Different in Configurations”, Masashi Murata, Hongfang Chi, Satoko 
Matsuo, Tamaki Kato, and Norikazu Nishino. The 48th Japanese Peptide symposium, 
Tokyo, Japan 2012. 
 
2. Poster presentation: “Assay of Histone Methyltransferases using Ac-Peptidyl-MCA 
as Substrates”, Norikazu Nishino, Tienabe K. Nsiama, Hongfang Chi, Yasushi 
Takemoto, Akihiro Ito, and Minoru Yoshida. The 31st European Peptide Symposium, 
Copenhagen, Denmark 2010. 
 
3. Poster presentation: “High Through Put Screening System for Histone 
Methyltransferase Inhibitors”, Hongfang Chi, Norikazu Nishino, Tienabe K. Nsiama, 
Yasushi Takemoto, Akihiro Ito, Minoru Yoshida. The 5th International Peptide 
Symposium, Kyoto, Japan 2010. 
 
4. Poster presentation: “Thirteen-membered Cyclic Tetrapeptides as Histone 
Deacetylase Inhibitors”, Hongfang Chi, Yasuhiko Otsuka, Tamaki Kato, Norikazu 
Nishino, Nobuyuki Kobashi, Akihiro Ito, and Minoru Yoshida. The 11th Chinese 
International Peptide symposium, Lan Zhou, China 2010. 
 
5. Poster presentation: “Convenient Preparation of N-Methyl-L-Lysine and 
Incorporation to Histone Tail Peptides”, Hongfang Chi, Md. Shahidul Islam, Nsiama 
 129 
 
Tienabe Kipassa, Tamaki Kato, and Norikazu Nishino. The 46th Japanese Peptide 
symposium, Kitakyushu, Japan 2009. 
 
